Cefepime-enmetazobactam

Medication reference

Monograph awaiting updateThis monograph will be updated in the future.

No original site article was mapped to this record. The available historical structured fields and official-source links are retained.

Historical first look: uses, mechanism, dosing context, and administration

Recovered v5.1 source content; historical, awaiting current review.

Id: cefepime-enmetazobactam
Source ID
H51-AE8233083D1A0473EB6C5871
Generic name: Cefepime-enmetazobactam
Source ID
H51-261A20DA03D25F29F28F32DC
Class: Antibacterial
Source ID
H51-E330C4DAB9F52D2D0C20C89A
Subclass: Cephalosporin plus beta-lactamase inhibitor
Source ID
H51-4FF0EF4417FF09657DD962A4
Primary uses: FDA-approved use: complicated urinary tract infection, including pyelonephritis, in adults 18 years and older when caused by designated susceptible organisms
Source ID
H51-32869A3A2E96012FCACBF657
Historical/current-label preparation reference; confirm current product availability and formulary status before any operational use
Source ID
H51-986E4BC5CB90418F72422BBB
Mechanism: The beta-lactam component inhibits penicillin-binding proteins and cell-wall synthesis; its partner protects or enhances activity against selected resistance mechanisms.
Source ID
H51-2D6C620B3925B91AA29651BE
Mechanism level: class_level
Source ID
H51-4175907E3A2A548DE4A5EE7E
Basic dosing orientation: Adult, eGFR 130 mL/min or greater | Existing preparation record; use current package insert for indication-specific selection | 2.5 g total (cefepime 2 g/enmetazobactam 0.5 g) every 8 hours | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion; Adult, eGFR 90 to 129 mL/min | Existing preparation record; use current package insert for indication-specific selection | 2.5 g total (cefepime 2 g/enmetazobactam 0.5 g) every 8 hours | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion
Source ID
H51-0159874E6F00308986C2F40A
Administration orientation: Infuse over 4 hours; Infuse over 2 hours
Source ID
H51-16C43EB3A32392A3674CF5AE
Renal and population orientation: Separate renal reference: Open Renal Dosing Master (opens in a new tab)Renal dose adjustment or interval modification is commonly required; verify the selected product label and patient-specific renal method.
Source ID
H51-90882F0C095F0EE2ECC06D3F
Key safety orientation: U.S. marketing status is listed as discontinued in Drugs@FDA. Do not treat this record as evidence that EXBLIFEP is currently available or on formulary.
Source ID
H51-FF37A29668AB4476B980B36B
Serious and occasionally fatal beta-lactam hypersensitivity reactions, including anaphylaxis and serious skin reactions, can occur.
Source ID
H51-7D3C7A877F98F15B783C11FA
Cefepime-associated neurotoxicity can include encephalopathy, aphasia, myoclonus, seizures, and nonconvulsive status epilepticus; risk is increased when renal adjustment is inadequate.
Source ID
H51-BD926C7F0FD55029726AE05B
Clostridioides difficile-associated diarrhea can occur during or after antibacterial therapy.
Source ID
H51-5E619D7BB99EFA892D1EE877
Coverage path: structured_local_snapshot
Source ID
H51-535EE35E31159206FBF30694
Coverage path label: Structured GlobalRPh route snapshot
Source ID
H51-A9887A859536ED51F3C91C02
Review note: First-look orientation only. Verify indication, patient population, weight basis, organ function, exact IV product, dose, concentration, compatibility, rate, and current labeling before use.
Source ID
H51-88EB2BBBE1C247932B5C720F
Search text: Cefepime-enmetazobactam Antibacterial Cephalosporin plus beta-lactamase inhibitor FDA-approved use: complicated urinary tract infection, including pyelonephritis, in adults 18 years and older when caused by designated susceptible organisms Historical/current-label preparation reference; confirm current product availability and formulary status before any operational use The beta-lactam component inhibits penicillin-binding proteins and cell-wall synthesis; its partner protects or enhances activity against selected resistance mechanisms. Adult, eGFR 130 mL/min or greater | Existing preparation record; use current package insert for indication-specific selection | 2.5 g total (cefepime 2 g/enmetazobactam 0.5 g) every 8 hours | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion; Adult, eGFR 90 to 129 mL/min | Existing preparation record; use current package insert for indication-specific selection | 2.5 g total (cefepime 2 g/enmetazobactam 0.5 g) every 8 hours | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion Infuse over 4 hours; Infuse over 2 hours Renal dose adjustment or interval modification is commonly required; verify the selected product label and patient-specific renal method. U.S. marketing status is listed as discontinued in Drugs@FDA. Do not treat this record as evidence that EXBLIFEP is currently available or on formulary. Serious and occasionally fatal beta-lactam hypersensitivity reactions, including anaphylaxis and serious skin reactions, can occur. Cefepime-associated neurotoxicity can include encephalopathy, aphasia, myoclonus, seizures, and nonconvulsive status epilepticus; risk is increased when renal adjustment is inadequate. Clostridioides difficile-associated diarrhea can occur during or after antibacterial therapy. Structured GlobalRPh route snapshot
Source ID
H51-E5D02D3BB5B701DBE44314E4
Official search url: https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Cefepime-enmetazobactam (opens in a new tab)
Source ID
H51-7D4D92DC17C96411E4168453
Official access mode: search
Source ID
H51-2002F1D0357638931761E999
Official access url: https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Cefepime-enmetazobactam (opens in a new tab)
Source ID
H51-920C7FF7BAE76FC69FF1DE98
Official search query: Cefepime-enmetazobactam
Source ID
H51-1D09051B1F9E2C83D00B8A32
Official access reason: A source-backed DailyMed search is available; select and confirm the exact IV product.
Source ID
H51-30B7113F7EC4FBA8017A0CC0

Product identifiers and clinical review status

This monograph will be updated in the future. Historical material is available where present in the original sources; full current exact-product and claim-level review remains pending.

Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.

What remains to be completed

Retrievable exact-product SPL XML with version, revision, retrieval date and reproducible hash
Clinically reviewed, individually identified statements with two exact source mappings
Exact formulation, strength, container, manufacturer/labeler, application and NDC reconciliation
Renal-function methods and dialysis/CRRT modality review where applicable
Mechanism provenance, clinical source disagreements and full medication-specific safety reconciliation

Supplemental historical fields

Restored-data provenance and review notes

Source release: 2026-08-31. Current clinical review is incomplete. Original uses of current, verified, or normalized describe the historical source. They do not inherit the status of separately reviewed statements. Product formulations and source dates can differ.

Current review annotations for historical renal, dialysis, mechanism, and product fields

Separate renal reference: Open Renal Dosing Master

Renal

Status

not_locally_normalized

Original classification

adjustment_required

Entries

General note

Preserve the source-specific renal-function basis. An indexed CrCl table is not interchangeable with unindexed CrCl or eGFR. Generic advice to check a method does not identify the equation for a dose row.

Dialysis

Status

no_local_structured_regimen

Entries

General note

Named modality alone does not establish applicability. CRRT subtype, effluent rate, residual renal function, timing and interruptions require review. Historical absence is not evidence that no guidance exists.

Mechanisms

Source kind
first_look
Local pointer
/mechanism
Original level
class_level
Provenance classification
historical_class_level
Label derived verified
false
Independently corroborated
false
Exact label section
Not recorded
Original source note
Not recorded
Review status
historical_unverified
Note
Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.

Future update

Status: pending_review
Message: This monograph will be updated in the future as current exact-product and claim-level review is completed.
Source unavailable: false
Reason: The historical content is restored; comprehensive contemporary verification remains incomplete.

No separate structured rows were bundled for IV push, continuous infusion, dialysis, CRRT. Historical article content and source links may cover these topics.

Historical dilution and intermittent infusion preparation

Recovered v5.1 source content; historical, awaiting current review.

Separate renal reference: Open Renal Dosing Master

Population	Amount	Reconstitution	Diluent	Final volume	Concentration	Rate	Stability	Notes
Source ID `H51-D196E903D1F068F1925A97C4` Adult, eGFR 130 mL/min or greater Source ID `H51-4BA3CAE4DE1EAA2C78885CC0`	2.5 g total (cefepime 2 g/enmetazobactam 0.5 g) every 8 hours Source ID `H51-6E5BE1BD0074139E07A8003D`	Withdraw 10 mL from a 250 mL bag of NS, D5W, or 2.5% dextrose/0.45% sodium chloride and use it to reconstitute one vial. Mix gently. The resulting vial concentration is 0.2 g/mL total product (cefepime 0.16 g/mL and enmetazobactam 0.04 g/mL), with an approximate vial volume of 13 mL. Not for direct injection. Source ID `H51-97271438D1B299C9564DF754`	Use the same NS, D5W, or 2.5% dextrose/0.45% sodium chloride solution for reconstitution and final dilution Source ID `H51-39AF97B6B18610F84539AAD8`	Return the entire reconstituted vial contents (approximately 13 mL) to the same labeled 250 mL infusion bag Source ID `H51-76D7186981C9A82A18435DF7`	Nominal 10 mg/mL total product based on the labeled 250 mL bag volume; actual concentration depends on container overfill and displacement Source ID `H51-53FDC3A1338547646E244FE9`	Infuse over 4 hours Source ID `H51-4A672707B818C7D5F4E5D493`	The prepared diluted solution may be refrigerated at 2 to 8 C for up to 4 hours before administration, but the infusion must be completed within 6 hours of dilution. Source ID `H51-325EC2C61F297EBE02F5BD9D`	Because the infusion lasts 4 hours and must be completed within 6 hours of dilution, no more than 2 hours can elapse between dilution and the start of infusion. The label uses MDRD-calculated eGFR. Source ID `H51-2849B41DE527DEDC7D7253FF`
Source ID `H51-8C0F90196D087B71AC03C226` Adult, eGFR 90 to 129 mL/min Source ID `H51-8DACC3A78539A68E282A35CD`	2.5 g total (cefepime 2 g/enmetazobactam 0.5 g) every 8 hours Source ID `H51-48C8AB8206085031295FA6A7`	Reconstitute one vial with 10 mL drawn from the final 250 mL NS, D5W, or 2.5% dextrose/0.45% sodium chloride bag. Resulting concentration: 0.2 g/mL total product; approximate vial volume: 13 mL. Not for direct injection. Source ID `H51-3AF13EA417EDAC398550D0C9`	Use the same solution for reconstitution and final dilution Source ID `H51-C739E115EF4B32E75EBB827B`	Return the entire reconstituted vial contents (approximately 13 mL) to the same labeled 250 mL infusion bag Source ID `H51-C53E1E98A3AEDD09DE33633E`	Nominal 10 mg/mL total product based on labeled bag volume; account for overfill and displacement Source ID `H51-0F9DD05F9FA20A5155854B88`	Infuse over 2 hours Source ID `H51-FBFFAA65C8C443C4893FB320`	Refrigerate the prepared diluted solution at 2 to 8 C for up to 4 hours before administration; complete infusion within 6 hours of dilution. Source ID `H51-8C053E00C8878E24DBEC9385`	Use aseptic technique. Inspect for particles and discoloration. Discard unused vial contents. Source ID `H51-AD661037F00E0E7A78F4F53C`
Source ID `H51-323651D699D0EE812E4B9E39` Adult, eGFR 60 to 89 mL/min Source ID `H51-6EE1CD75030B17E26D7FB59C`	2.5 g total (cefepime 2 g/enmetazobactam 0.5 g) every 8 hours Source ID `H51-97D119FEB63310F57915690F`	Reconstitute one vial with 10 mL drawn from the final 250 mL bag. Resulting concentration: 0.2 g/mL total product; approximate vial volume: 13 mL. Not for direct injection. Source ID `H51-AD47895B840E53ED325963D3`	NS, D5W, or 2.5% dextrose/0.45% sodium chloride; use the same solution for both steps Source ID `H51-EDEF60A813865A84C600A1F7`	Return the entire reconstituted vial contents (approximately 13 mL) to the same labeled 250 mL infusion bag Source ID `H51-601EDE570900603541A900F6`	Nominal 10 mg/mL total product based on labeled bag volume; account for overfill and displacement Source ID `H51-D5DA8133151CD58E842ABED3`	Infuse over 2 hours Source ID `H51-ECE5FA3C1FBE4FC567069270`	Refrigerate the prepared diluted solution at 2 to 8 C for up to 4 hours before administration; complete infusion within 6 hours of dilution. Source ID `H51-78B34AAADA105C07ADD578F5`	Monitor renal function and revise the regimen if eGFR changes during therapy. Source ID `H51-AF91120DDCF7608FD8CE947C`
Source ID `H51-5A781E30EF29A81D8C9CA51D` Adult, eGFR 30 to 59 mL/min Source ID `H51-118E4D90656CE0087B5EF9F8`	1.25 g total (cefepime 1 g/enmetazobactam 0.25 g) every 8 hours Source ID `H51-AF9FA542E797464CD0F965A0`	Reconstitute one 2.5 g vial with 10 mL drawn from the final 250 mL bag. After dissolution, withdraw 6.5 mL of the reconstituted 0.2 g/mL total-product solution. Not for direct injection. Source ID `H51-3BFDD781E1C80151429EF30E`	NS, D5W, or 2.5% dextrose/0.45% sodium chloride; use the same solution for both steps Source ID `H51-A9F1F8ADB56C2FBDE6F9575F`	Add 6.5 mL to the same labeled 250 mL infusion bag Source ID `H51-463D1195D494F8CFF55AD072`	Nominal 5 mg/mL total product based on labeled bag volume; account for overfill and displacement Source ID `H51-003EFB8588AFAFED1C7AED18`	Infuse over 2 hours Source ID `H51-658ADF37E7D1B1CD3D5C060F`	Refrigerate the prepared diluted solution at 2 to 8 C for up to 4 hours before administration; complete infusion within 6 hours of dilution. Source ID `H51-8EB0C35BDAAA191E65A89A73`	Discard the unused reconstituted vial portion. Monitor changing renal function at least daily as directed in the label. Source ID `H51-69685019FDF3B28A42E07440`
Source ID `H51-71509B7B7AB96E24A8868E07` Adult, eGFR 15 to 29 mL/min Source ID `H51-71931975FF12B9937AE12B9C`	1.25 g total (cefepime 1 g/enmetazobactam 0.25 g) every 12 hours Source ID `H51-8064DF2509C7433D74D6F9FD`	Reconstitute one 2.5 g vial with 10 mL drawn from the final 250 mL bag. After dissolution, withdraw 6.5 mL of the reconstituted 0.2 g/mL total-product solution. Not for direct injection. Source ID `H51-960E8CAE61D05AD7AFC11DF5`	NS, D5W, or 2.5% dextrose/0.45% sodium chloride; use the same solution for both steps Source ID `H51-F84C3311048C781F1B70F3F7`	Add 6.5 mL to the same labeled 250 mL infusion bag Source ID `H51-A708E40BF88304F4FFD85C5A`	Nominal 5 mg/mL total product based on labeled bag volume; account for overfill and displacement Source ID `H51-44E970161B71822BFBDB1424`	Infuse over 2 hours Source ID `H51-B401F472B75A687EEDEF2B2E`	Refrigerate the prepared diluted solution at 2 to 8 C for up to 4 hours before administration; complete infusion within 6 hours of dilution. Source ID `H51-F1AC441C3F7FF6BD442D66D2`	Discard the unused reconstituted vial portion. Reassess eGFR during therapy. Source ID `H51-2A1310D3820699B3F3E708DC`
Source ID `H51-D14B7CE8053984F69442E4B2` Adult, eGFR below 15 mL/min or intermittent hemodialysis - day 1 loading dose Source ID `H51-467E6F649E5ACFD85C63BCEB`	1.25 g total (cefepime 1 g/enmetazobactam 0.25 g) once on the first day Source ID `H51-D0D4C18BA42D6A13F64AB0AC`	Reconstitute one 2.5 g vial with 10 mL drawn from the final 250 mL bag. Withdraw 6.5 mL of the reconstituted 0.2 g/mL total-product solution. Not for direct injection. Source ID `H51-200963F2DFE98D5A04C0C69C`	NS, D5W, or 2.5% dextrose/0.45% sodium chloride; use the same solution for both steps Source ID `H51-F2CC831D6E34FAA320732E1D`	Add 6.5 mL to the same labeled 250 mL infusion bag Source ID `H51-6E5928D8F3DD8F063A82E168`	Nominal 5 mg/mL total product based on labeled bag volume; account for overfill and displacement Source ID `H51-6401275A7C5ADEE07DC0E700`	Infuse over 2 hours Source ID `H51-3246A90E56A1BB1BD4659755`	Refrigerate the prepared diluted solution at 2 to 8 C for up to 4 hours before administration; complete infusion within 6 hours of dilution. Source ID `H51-3F7F4035F394FDCE871FD183`	For intermittent hemodialysis, complete the hemodialysis session before EXBLIFEP dosing. Source ID `H51-0C6BF4F33A4B9DE45550B77B`
Source ID `H51-B755D14F53D6F4F096D2A14B` Adult, eGFR below 15 mL/min or intermittent hemodialysis - maintenance Source ID `H51-038974CB4DC5BA78BF36B92A`	0.625 g total (cefepime 0.5 g/enmetazobactam 0.125 g) every 24 hours after the day 1 loading dose Source ID `H51-2BF3A14659386DC6816C179E`	Reconstitute one 2.5 g vial with 10 mL drawn from the final 250 mL bag. Withdraw 3.3 mL of the reconstituted 0.2 g/mL total-product solution. Not for direct injection. Source ID `H51-5E8CC2C0D0D8FDCC864B1D85`	NS, D5W, or 2.5% dextrose/0.45% sodium chloride; use the same solution for both steps Source ID `H51-8250B696048EDF32FA2F18A1`	Add 3.3 mL to the same labeled 250 mL infusion bag Source ID `H51-F37AB76B3842CD69FD7846EE`	Nominal 2.5 mg/mL total product based on labeled bag volume; account for overfill and displacement Source ID `H51-CDF1AB822BAFADD7E8F71BFF`	Infuse over 2 hours Source ID `H51-30B686C3E5C322087EF785A3`	Refrigerate the prepared diluted solution at 2 to 8 C for up to 4 hours before administration; complete infusion within 6 hours of dilution. Source ID `H51-C81FA0392A89498C804A1395`	For intermittent hemodialysis, dose after completion of the hemodialysis session and, when possible, at the same time each day. Discard unused vial contents. Source ID `H51-7DBE25D53BA7F12CDE398DB6`

Historical indication and population dosing

Recovered tables and source-separated snapshots; full clinical revalidation remains pending.

Existing dose and route snapshots

Separate renal reference: Open Renal Dosing Master

Route	Population	Indication	Dose	Interval	Duration	Administration	Source level	Notes
Source ID `H51-9F72130096C0AAA9E90B42B2` IV infusion Source ID `H51-8ACBC4CDCE4E8C82BC8D7009`	Adult, eGFR 130 mL/min or greater Source ID `H51-5316329AB1D3EDB832A9E400`	Existing preparation record; use current package insert for indication-specific selection Source ID `H51-CE594B04A950C91026695A63`	2.5 g total (cefepime 2 g/enmetazobactam 0.5 g) every 8 hours Source ID `H51-D54B38C2D5C23BB701E8D829`	Not normalized in the preparation record Source ID `H51-21B93F309C7015674A798A72`	See current package insert and professional guidance Source ID `H51-6CF2E535FA078ADDD0786B01`	Infuse over 4 hours Source ID `H51-EE3EB8DA4B6F3207302E8DD4`	Existing GlobalRPh structured preparation snapshot Source ID `H51-C434E22F58DD11AF838ADFCB`	Because the infusion lasts 4 hours and must be completed within 6 hours of dilution, no more than 2 hours can elapse between dilution and the start of infusion. The label uses MDRD-calculated eGFR. Source ID `H51-FFD7A27ED6B99611C4E5DC7F`
Source ID `H51-BC36A6C2B3D9F229759A8C15` IV infusion Source ID `H51-AD67F836A58A26625EB1F65F`	Adult, eGFR 90 to 129 mL/min Source ID `H51-BA0B3BA4ADC229735EAEC7BD`	Existing preparation record; use current package insert for indication-specific selection Source ID `H51-2E087C9F18EF3CC536518513`	2.5 g total (cefepime 2 g/enmetazobactam 0.5 g) every 8 hours Source ID `H51-7544CF088E51D89329AC61CB`	Not normalized in the preparation record Source ID `H51-A445F0537F0684A392A3AB90`	See current package insert and professional guidance Source ID `H51-D8CAF0C7657BFD8F44D12AF0`	Infuse over 2 hours Source ID `H51-0599FB426E25B91DA14D3BBB`	Existing GlobalRPh structured preparation snapshot Source ID `H51-2A583F71D4EE5AE0ACC1BEB3`	Use aseptic technique. Inspect for particles and discoloration. Discard unused vial contents. Source ID `H51-5C5C24A051B084EE6B1EE595`
Source ID `H51-3B089FAD85DDDD53B10AA104` IV infusion Source ID `H51-1966B997BACC4B97F616A722`	Adult, eGFR 60 to 89 mL/min Source ID `H51-8591039AB70253A22460F202`	Existing preparation record; use current package insert for indication-specific selection Source ID `H51-69633B18C9C5BCB712F11A8C`	2.5 g total (cefepime 2 g/enmetazobactam 0.5 g) every 8 hours Source ID `H51-5C71DB7F2B93A9841CAA7234`	Not normalized in the preparation record Source ID `H51-FEE0BD9DC4CBB40CA5655F20`	See current package insert and professional guidance Source ID `H51-77CB744F188E2ADB90951488`	Infuse over 2 hours Source ID `H51-8249BAA1A6087E676356C809`	Existing GlobalRPh structured preparation snapshot Source ID `H51-4550EFD5067A5BF9C9EE746E`	Monitor renal function and revise the regimen if eGFR changes during therapy. Source ID `H51-7AECB625F695F716A8988606`
Source ID `H51-3DB86E3B025F1DB8BF07D37F` IV infusion Source ID `H51-5FB80CA33B9BB52DC1B57A0C`	Adult, eGFR 30 to 59 mL/min Source ID `H51-9EAD519DA507A1C8D4E1198A`	Existing preparation record; use current package insert for indication-specific selection Source ID `H51-3D58D857D4B3A70B7F094961`	1.25 g total (cefepime 1 g/enmetazobactam 0.25 g) every 8 hours Source ID `H51-0997B119ED48EE87695C3B35`	Not normalized in the preparation record Source ID `H51-6FA1688AC9F9877583B0B41C`	See current package insert and professional guidance Source ID `H51-C7405B915EAB7FAC692D1D5B`	Infuse over 2 hours Source ID `H51-5E35EBBFD13CAC16FE87B953`	Existing GlobalRPh structured preparation snapshot Source ID `H51-51CC3922F040B55A962BBF4E`	Discard the unused reconstituted vial portion. Monitor changing renal function at least daily as directed in the label. Source ID `H51-7B1D9F3BCCFDAED71BD2915F`
Source ID `H51-B1E9D55B87DCA3EBDD6EC96F` IV infusion Source ID `H51-BD1849EC746CBDC3E1CA53EA`	Adult, eGFR 15 to 29 mL/min Source ID `H51-7726D8BDB9EF8C6D1B21ECE3`	Existing preparation record; use current package insert for indication-specific selection Source ID `H51-6A27D91150FFC10BBBC44089`	1.25 g total (cefepime 1 g/enmetazobactam 0.25 g) every 12 hours Source ID `H51-492D2E689AF1C7BE4418457D`	Not normalized in the preparation record Source ID `H51-EAC3D7606767B1CC68DF9474`	See current package insert and professional guidance Source ID `H51-E52036DB004BE873FA2A3B31`	Infuse over 2 hours Source ID `H51-D13FCE8233717AD482D1690C`	Existing GlobalRPh structured preparation snapshot Source ID `H51-3447A8DA589FD573204D5A13`	Discard the unused reconstituted vial portion. Reassess eGFR during therapy. Source ID `H51-8D34B47623F9BBA6D0F44F17`
Source ID `H51-B0DE2B72D5102091261069FD` IV infusion Source ID `H51-D095D62B67BCC90A7489EED6`	Adult, eGFR below 15 mL/min or intermittent hemodialysis - day 1 loading dose Source ID `H51-9A031E5FB04AABDE7F03D4DC`	Existing preparation record; use current package insert for indication-specific selection Source ID `H51-51A989B0501BE33C31710DAB`	1.25 g total (cefepime 1 g/enmetazobactam 0.25 g) once on the first day Source ID `H51-B95E22FF43F60611A410718D`	Not normalized in the preparation record Source ID `H51-1CBEED715CF8A380CE18CBC8`	See current package insert and professional guidance Source ID `H51-39309D304BD13885FD424EA2`	Infuse over 2 hours Source ID `H51-60268302780A0618EFC7A3C5`	Existing GlobalRPh structured preparation snapshot Source ID `H51-63135ADB46A1C437AF37AAC4`	For intermittent hemodialysis, complete the hemodialysis session before EXBLIFEP dosing. Source ID `H51-4B81FF0827571A5132A26E76`
Source ID `H51-2A22FC4FD11C65FA34D33BA5` IV infusion Source ID `H51-5EB401B8D6B413B73EED8018`	Adult, eGFR below 15 mL/min or intermittent hemodialysis - maintenance Source ID `H51-2A973A522840CE0AC0BEA052`	Existing preparation record; use current package insert for indication-specific selection Source ID `H51-B918BAD928938E208190D9E1`	0.625 g total (cefepime 0.5 g/enmetazobactam 0.125 g) every 24 hours after the day 1 loading dose Source ID `H51-32BBEF777B11823C71AC5714`	Not normalized in the preparation record Source ID `H51-16A1EA876C0FFB45ACDAA320`	See current package insert and professional guidance Source ID `H51-770AC4527EDC7B2B762F2A30`	Infuse over 2 hours Source ID `H51-92DB9971916A99657355FC35`	Existing GlobalRPh structured preparation snapshot Source ID `H51-0994A2448A5D17EEA4588D01`	For intermittent hemodialysis, dose after completion of the hemodialysis session and, when possible, at the same time each day. Discard unused vial contents. Source ID `H51-36AC0B0DB25B96A56BEEA93F`

Historical renal-function guidance

Recovered v5.1 source content; historical, awaiting current review.

Separate renal reference: Open Renal Dosing Master

Classification: adjustment_required
Source ID
H51-F2B4BC28937F41F72A65090C
Summary: Renal dose adjustment or interval modification is commonly required; verify the selected product label and patient-specific renal method.
Source ID
H51-32879C3BA0FC61EE8487CA59
Method note: Use the renal function estimate and body-size convention specified by the selected label or institutional protocol. Do not interchange Cockcroft-Gault CrCl, indexed eGFR, and de-indexed eGFR without confirming the dosing source.
Source ID
H51-D30DFAFD002C47EA1699E31D

Historical Common IV uses

Recovered v5.1 source content; historical, awaiting current review.

FDA-approved use: complicated urinary tract infection, including pyelonephritis, in adults 18 years and older when caused by designated susceptible organisms
Source ID
H51-2996803C045A63D8EC326913
Historical/current-label preparation reference; confirm current product availability and formulary status before any operational use
Source ID
H51-74F6193CA6F4393F211716FF

Historical Warnings and safeguards

Recovered v5.1 source content; historical, awaiting current review.

Separate renal reference: Open Renal Dosing Master

U.S. marketing status is listed as discontinued in Drugs@FDA. Do not treat this record as evidence that EXBLIFEP is currently available or on formulary.
Source ID
H51-7DF9490C480A14F96F409D7E
Serious and occasionally fatal beta-lactam hypersensitivity reactions, including anaphylaxis and serious skin reactions, can occur.
Source ID
H51-7F4DB032BF46117AF82B5E0D
Cefepime-associated neurotoxicity can include encephalopathy, aphasia, myoclonus, seizures, and nonconvulsive status epilepticus; risk is increased when renal adjustment is inadequate.
Source ID
H51-57133BC4DDA6DCB04E3C3647
Clostridioides difficile-associated diarrhea can occur during or after antibacterial therapy.
Source ID
H51-1432350FD9333BA1FC2C6FC3
The reconstituted vial solution is not for direct injection and must be immediately further diluted.
Source ID
H51-F48DFDD8363DEE35C70FA32D

Historical Monitoring

Recovered v5.1 source content; historical, awaiting current review.

Separate renal reference: Open Renal Dosing Master

Current product availability, U.S. marketing status, and local formulary status before use
Source ID
H51-32F65B0BC59FDE344C33E4D4
Serum creatinine and eGFR at least daily when renal function is changing
Source ID
H51-814AFE9A1FC4CE9AE110A46A
Mental status, myoclonus, seizure activity, and other neurotoxicity findings
Source ID
H51-4B3CDBDA465ED5BC6D04FC81
Hypersensitivity during administration
Source ID
H51-8C5DAD38A5A477195455EA9C
Clinical and microbiologic response
Source ID
H51-A3260A06EBBEA694C012581A
Diarrhea and other findings concerning for C. difficile infection
Source ID
H51-45DC213DF6608B408724144B

Historical Compatibility

Recovered v5.1 source content; historical, awaiting current review.

Compatible preparation fluids in the U.S. label: 0.9% Sodium Chloride Injection, 5% Dextrose Injection, and 2.5% Dextrose/0.45% Sodium Chloride Injection.
Source ID
H51-96965FA7B79269B0AB0B9D1B
Use the same solution for vial reconstitution and final bag dilution.
Source ID
H51-86E859AB54A41F0FA9D2B2D9
Compatibility with other drugs for administration has not been established; do not combine in the same solution without an approved compatibility source.
Source ID
H51-38FCE6F318CFE5B47D188029

Historical Stability notes

Recovered v5.1 source content; historical, awaiting current review.

The reconstituted solution must be immediately further diluted in the same 250 mL bag used to obtain the 10 mL reconstitution volume.
Source ID
H51-DBF37CAEDE65827C83E6A26A
The prepared diluted solution may be stored refrigerated at 2 to 8 C for up to 4 hours before administration.
Source ID
H51-36BDAFA8839874363E813FD2
The intravenous infusion must be completed within 6 hours of dilution. This product-specific completion limit is shorter than many sterility-based BUD ceilings and remains controlling.
Source ID
H51-2AE8020D9D22E7F36CF15E3F
Discard unused portions from the single-dose vial.
Source ID
H51-38C7E76A01BDFBE00180C95C

Historical supplemental professional sources

Recovered v5.1 source content; historical, awaiting current review.

Label	Url	Kind
Source ID `H51-58042A72B369425C41F51A55` UCSF adult antimicrobial dosing, non-dialysis Source ID `H51-89F6F0DC2E03C1C9FAFAE2D3`	https://idmp.ucsf.edu/adult-antimicrobial-dosing-non-dialysis (opens in a new tab) Source ID `H51-F83D2910C7BEB7AE3F1D885B`	Professional institutional guidance Source ID `H51-A7E24F6163A389D3CCF259D9`
Source ID `H51-667DDB0FB655FE20462B878A` UCSF antimicrobial dosing in intermittent and continuous hemodialysis Source ID `H51-E5E1EE59F28DEAE3B7A2F1B1`	https://idmp.ucsf.edu/antimicrobial-dosing-intermittent-continuous-hemodialysis (opens in a new tab) Source ID `H51-D765765B40766F5A13F4090C`	Professional institutional guidance Source ID `H51-3F410F1043B7EF867B7A8BB0`
Source ID `H51-37486DF66AE06227ED4A2C9C` UCSF pediatric antimicrobial dosing Source ID `H51-0DB22ED4407FBA70925DD143`	https://idmp.ucsf.edu/pediatric-antimicrobial-dosing-benioff-childrens-hospitals (opens in a new tab) Source ID `H51-C1827080793AF81180C26405`	Professional institutional guidance Source ID `H51-B6C7FF31800707759219B3C6`
Source ID `H51-B74E4ACFB4F51CAF7FE57CB3` UCSF neonatal antimicrobial dosing Source ID `H51-8DF8E1AE9B97CB701412E075`	https://idmp.ucsf.edu/neonatal-antimicrobial-dosing-benioff-childrens-hospitals (opens in a new tab) Source ID `H51-3A29A44C99361D2A91A9F7FB`	Professional institutional guidance Source ID `H51-8CBD5B21C1054113A9D6901E`

Other recovered source fields and original editorial metadata

Original status words such as current, verified, or normalized describe the historical source release. They do not change the clinical review status of this release.

Catalog source fields

Id

cefepime-enmetazobactam

Source ID

H51-46EB92497506B74D51402FCD

Generic name

Cefepime-enmetazobactam

Source ID

H51-F49C0CBA6634C6E5D9C26355

Brand names

Exblifep
Source ID
H51-276940F4CC87ABD001F0A943

Aliases

cefepime enmetazobactam
Source ID
H51-708FA9719A4FAA9F0720FE58

Class

Antibacterial

Source ID

H51-E3AB3B1F00B618F44A837C03

Subclass

Cephalosporin plus beta-lactamase inhibitor

Source ID

H51-265F06C371E911BBE622CC52

Summary

Separate renal reference: Open Renal Dosing MasterFixed cefepime 2 g plus enmetazobactam 0.5 g single-dose vial approved for adult complicated urinary tract infection. The U.S. prescribing information provides renal-function-specific regimens, reconstitution, final bag preparation, and a six-hour completion limit. Drugs@FDA currently lists the U.S. product marketing status as discontinued, so this record is retained as a clearly labeled regulatory and preparation reference rather than an active formulary recommendation.

Source ID

H51-91A22AB8AC71156B422A9F00

Populations

Separate renal reference: Open Renal Dosing Master

Adult
Source ID
H51-7F5CDB53D1108B230D3FB162
Renal impairment
Source ID
H51-8FFC8A2E617FCB175126954E
Intermittent hemodialysis
Source ID
H51-4AC8B9472D50CA3310616BB9

Evidence tier

Current-label candidate - verify exact product - U.S. marketing discontinued

Source ID

H51-2B547F1549342AC7A7D57B52

High alert

false

Source ID

H51-84408EBF689BF7A3ADA4C819

Hazardous

false

Source ID

H51-9A333A437A202065F03C12F3

Status

Discontinued in U.S. marketing status

Source ID

H51-503D78AE9E06C6D722988E23

Reviewed

2026-08-29

Source ID

H51-EF29C28F5783A3FC581A29B6

Version added

1.2

Source ID

H51-7D956356D3881E7936A40292

Version updated

1.3

Source ID

H51-BCB71E9AE7A2A34B849E4D3B

Sources

Label	Url	Kind
Source ID `H51-A2D7B8C06B1869216F4C91B5` FDA Drugs@FDA overview for NDA 216165 (current U.S. marketing status and label history) Source ID `H51-B2CB5FCD16AFF8B972A92E4E`	https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165 (opens in a new tab) Source ID `H51-2681BA71C13608180679EB27`	Regulatory Source ID `H51-D1F2D7965FA78F0A5280720F`
Source ID `H51-481400DAD7BF0F589D66013D` FDA EXBLIFEP full prescribing information, original approval label Source ID `H51-637E6C8DDFE7310661A2E558`	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216165s000lbl.pdf (opens in a new tab) Source ID `H51-E2EFE8603E158F813A3D63A8`	Primary Source ID `H51-BDBEB77E3400B2C1A44385E0`

Clinical release verification

Audit version: 3.4
Source ID
H51-6A812AAD7EE3BA9EB3CF0FC1
Audited on: 2026-08-30
Source ID
H51-4BCE6FA778EDFCFB8696DD0B
Level: amber
Source ID
H51-D253CE70F551AFE9D13EBA4D
Release gate: trusted_professional_source_present_exact_label_unconfirmed
Source ID
H51-54A75AF25C67E4243E63403F
Exact current label candidate: false
Source ID
H51-13DC94D6086E9231D66FF494
Numeric support ratio: 0
Source ID
H51-299A7DCDAE97A236E428A2B8
Reference url count: 6
Source ID
H51-BC20F6981681DA0C84FAE168
Broken reference count: 0
Source ID
H51-653788941C60CFB1A72F78CB
Point of use confirmation required: true
Source ID
H51-A22B0D9695A7D0A35373B7E0
Note: Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
Source ID
H51-BC22D4166245BAFC309A0EE0
Dailymed search url: https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Cefepime-enmetazobactam (opens in a new tab)
Source ID
H51-8DB15192071EF621568B0F93

Dosing source fields

Id

cefepime-enmetazobactam

Source ID

H51-EECB65B75CE753EF7BA479B7

Generic name

Cefepime-enmetazobactam

Source ID

H51-59EBEE32D757C99BD17FC4F1

Coverage status

direct_official_label_access_plus_local_snapshot

Source ID

H51-15F962620A951F2B578250F0

Package insert

Query name: Cefepime-enmetazobactam
Source ID
H51-98779493A7CA6A2403CE1042
Product and route must match: true
Source ID
H51-5A958FAFC7696605F738E368
Live current label enabled: false
Source ID
H51-C7B64CC3061AC0F95B8D81BE
Source priority: Reviewed local summary when available, then a verified DailyMed label or product search when available, followed by professional references and institutional policy.
Source ID
H51-38B18947FAE8F9DEA98A3445
Direct official label access enabled: true
Source ID
H51-AA7A39D2E57BB7958F233654
Outbound server request required: false
Source ID
H51-9EF3C5386C5616D7A71AD88F
Local summary status: not_bundled
Source ID
H51-8B1AECADCDDFCE187B14467A

Clinical review

Locally normalized: false
Source ID
H51-1C48A7F002688EA43F746185
Reviewed: 2026-08-29
Source ID
H51-C4B7E9C105E2105DFFD436A2
Status: Direct official package-insert access enabled; indication-specific local normalization pending.
Source ID
H51-28CAA1BEAF9FA4605351CD5E

Clinical release verification

Audit version: 3.4
Source ID
H51-4579819D41F9779464F03B16
Audited on: 2026-08-30
Source ID
H51-0470C4CDB96C9EB85A17B54B
Level: amber
Source ID
H51-5C0643BDFB92E0777DB3B7DB
Release gate: trusted_professional_source_present_exact_label_unconfirmed
Source ID
H51-54CBA48A3B18B647C369B2DF
Exact current label candidate: false
Source ID
H51-A9A56937D5486CB65EA21F97
Numeric support ratio: 0
Source ID
H51-2C794906157C1E393D174E3D
Reference url count: 6
Source ID
H51-A626A40B88B8BC29814881BB
Broken reference count: 0
Source ID
H51-528E1732D9908DD78ECBB427
Point of use confirmation required: true
Source ID
H51-19BEE3F6420BE6EBC958E714
Note: Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
Source ID
H51-54EF86654C58113AE7B626AA
Dailymed search url: https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Cefepime-enmetazobactam (opens in a new tab)
Source ID
H51-42509450A270397167D013C8

Historical preparation assessment

Recovered v5.1 source content; historical, awaiting current review.

cefepime-enmetazobactam

Source ID

H51-EEFB6393B6F063B308597572

Name

Cefepime-enmetazobactam

Source ID

H51-FFCCD6558AF38982DAA76A07

Brands

Exblifep

Source ID

H51-F413A2D9AC7D4A659D82C09F

Therapeutic class

Antibacterial

Source ID

H51-7B6D3E6AA3F188883FD83DF5

Review version

3.1

Source ID

H51-68147BABFD0B964BE1DB3DE0

Review date

2026-08-30

Source ID

H51-84CAB8C693D96AE8C35EE21F

Release status

structured_record_current_label_not_confirmed

Source ID

H51-A9EF30C666F38EEF3C5C174F

Market status

Status: verified_or_explicitly_flagged_discontinued
Source ID
H51-B5EFED6805C16991002EE6E6
Basis: existing catalog or editorial record
Source ID
H51-C0460F7CA2924A104A0563CC

Ten point assessment

Exact formulation

Separate renal reference: Open Renal Dosing MasterMonitor changing renal function at least daily as directed in the label. | route: IV infusion | population: Adult, eGFR 15 to 29 mL/min | indication: Existing preparation record; use current package insert for indication-specific selection | dose: 1.25 g total (cefepime 1 g/enmetazobactam 0.25 g) every 12 hours | interval: Not normalized in the preparation record | duration: See current package insert and professional guidance | administration: Infuse over 2 hours | source_level: Existing GlobalRPh structured preparation snapshot | notes: Discard the unused reconstituted vial portion. Drugs@FDA currently lists the U.S. product marketing status as discontinued, so this record is retained as a clearly labeled regulatory and preparation reference rather than an active formulary recommendation. | common_uses: FDA-approved use: complicated urinary tract infection, including pyelonephritis, in adults 18 years and older when caused by designated susceptible organisms | Historical/current-label preparation reference; confirm current product availability and formulary status before any operational use | preparations: population: Adult, eGFR 130 mL/min or greater | amount: 2.5 g total (cefepime 2 g/enmetazobactam 0.5 g) every 8 hours | reconstitution: Withdraw 10 mL from a 250 mL bag of NS, D5W, or 2.5% dextrose/0.45% sodium chloride and use it to reconstitute one vial. The resulting vial concentration is 0.2 g/mL total product (cefepime 0.16 g/mL and enmetazobactam 0.04 g/mL), with an approximate vial volume of 13 mL. Not for direct injection. | diluent: Use the same NS, D5W, or 2.5% dextrose/0.45% sodium chloride solution for reconstitution and final dilution | final_volume: Return the entire reconstituted vial contents (approximately 13 mL) to the same labeled 250 mL infusion bag | concentration: Nominal 10 mg/mL total product based on the labeled 250 mL bag volume; actual concentration depends on container overfill and displacement | rate: Infuse over 4 hours | stability: The prepared diluted solution may be refrigerated at 2 to 8 C for up to 4 hours before administration, but the infusion must be completed within 6 hours of dilution. | notes: Because the infusion lasts 4 hours and must be completed within 6 hours of dilution, no more than 2 hours can elapse between dilution and the start of infusion. The label uses MDRD-calculated eGFR. | population: Adult, eGFR 90 to 129 mL/min | amount: 2.5 g total (cefepime 2 g/enmetazobactam 0.5 g) every 8 hours | reconstitution: Reconstitute one vial with 10 mL drawn from the final 250 mL NS, D5W, or 2.5% dextrose/0.45% sodium chloride bag.

Source ID

H51-FC5288D4BA4C9AB79E5F75E8

Reconstitution concentration

Withdraw 10 mL from a 250 mL bag of NS, D5W, or 2.5% dextrose/0.45% sodium chloride and use it to reconstitute one vial. Mix gently. The resulting vial concentration is 0.2 g/mL total product (cefepime 0.16 g/mL and enmetazobactam 0.04 g/mL), with an approximate vial volume of 13 mL. Not for direct injection. Reconstitute one vial with 10 mL drawn from the final 250 mL NS, D5W, or 2.5% dextrose/0.45% sodium chloride bag. Resulting concentration: 0.2 g/mL total product; approximate vial volume: 13 mL. Not for direct injection. Reconstitute one vial with 10 mL drawn from the final 250 mL bag. Resulting concentration: 0.2 g/mL total product; approximate vial volume: 13 mL. Not for direct injection. Reconstitute one 2.5 g vial with 10 mL drawn from the final 250 mL bag. After dissolution, withdraw 6.5 mL of the reconstituted 0.2 g/mL total-product solution. Not for direct injection. Reconstitute one 2.5 g vial with 10 mL drawn from the final 250 mL bag. Withdraw 6.5 mL of the reconstituted 0.2 g/mL total-product solution. Not for direct injection. Reconstitute one 2.5 g vial with 10 mL drawn from the final 250 mL bag. Withdraw 3.3 mL of the reconstituted 0.2 g/mL total-product solution. Not for direct injection.

Source ID

H51-64478A7DC1C492FE03D0BD9C

Maximum or recommended final concentration

Separate renal reference: Open Renal Dosing MasterNot for direct injection. | diluent: Use the same NS, D5W, or 2.5% dextrose/0.45% sodium chloride solution for reconstitution and final dilution | final_volume: Return the entire reconstituted vial contents (approximately 13 mL) to the same labeled 250 mL infusion bag | concentration: Nominal 10 mg/mL total product based on the labeled 250 mL bag volume; actual concentration depends on container overfill and displacement | rate: Infuse over 4 hours | stability: The prepared diluted solution may be refrigerated at 2 to 8 C for up to 4 hours before administration, but the infusion must be completed within 6 hours of dilution. | notes: Because the infusion lasts 4 hours and must be completed within 6 hours of dilution, no more than 2 hours can elapse between dilution and the start of infusion. Not for direct injection. | diluent: Use the same solution for reconstitution and final dilution | final_volume: Return the entire reconstituted vial contents (approximately 13 mL) to the same labeled 250 mL infusion bag | concentration: Nominal 10 mg/mL total product based on labeled bag volume; account for overfill and displacement | rate: Infuse over 2 hours | stability: Refrigerate the prepared diluted solution at 2 to 8 C for up to 4 hours before administration; complete infusion within 6 hours of dilution. | notes: Use aseptic technique. Not for direct injection. | diluent: NS, D5W, or 2.5% dextrose/0.45% sodium chloride; use the same solution for both steps | final_volume: Return the entire reconstituted vial contents (approximately 13 mL) to the same labeled 250 mL infusion bag | concentration: Nominal 10 mg/mL total product based on labeled bag volume; account for overfill and displacement | rate: Infuse over 2 hours | stability: Refrigerate the prepared diluted solution at 2 to 8 C for up to 4 hours before administration; complete infusion within 6 hours of dilution. | notes: Monitor renal function and revise the regimen if eGFR changes during therapy. | population: Adult, eGFR 30 to 59 mL/min | amount: 1.25 g total (cefepime 1 g/enmetazobactam 0.25 g) every 8 hours | reconstitution: Reconstitute one 2.5 g vial with 10 mL drawn from the final 250 mL bag. Not for direct injection. | diluent: NS, D5W, or 2.5% dextrose/0.45% sodium chloride; use the same solution for both steps | final_volume: Add 6.5 mL to the same labeled 250 mL infusion bag | concentration: Nominal 5 mg/mL total product based on labeled bag volume; account for overfill and displacement | rate: Infuse over 2 hours | stability: Refrigerate the prepared diluted solution at 2 to 8 C for up to 4 hours before administration; complete infusion within 6 hours of dilution. | notes: Discard the unused reconstituted vial portion. Not for direct injection. | diluent: NS, D5W, or 2.5% dextrose/0.45% sodium chloride; use the same solution for both steps | final_volume: Add 6.5 mL to the same labeled 250 mL infusion bag | concentration: Nominal 5 mg/mL total product based on labeled bag volume; account for overfill and displacement | rate: Infuse over 2 hours | stability: Refrigerate the prepared diluted solution at 2 to 8 C for up to 4 hours before administration; complete infusion within 6 hours of dilution. | notes: Discard the unused reconstituted vial portion.

Source ID

H51-A83F9F5D851832D0E0A68A43

Appropriate standardized containers

Return the entire reconstituted vial contents (approximately 13 mL) to the same labeled 250 mL infusion bag Add 6.5 mL to the same labeled 250 mL infusion bag Add 3.3 mL to the same labeled 250 mL infusion bag

Source ID

H51-D35B6A76D32F2DE2ED6EC042

Adult dosing range

2.5 g total (cefepime 2 g/enmetazobactam 0.5 g) every 8 hours 1.25 g total (cefepime 1 g/enmetazobactam 0.25 g) every 8 hours 1.25 g total (cefepime 1 g/enmetazobactam 0.25 g) every 12 hours 1.25 g total (cefepime 1 g/enmetazobactam 0.25 g) once on the first day 0.625 g total (cefepime 0.5 g/enmetazobactam 0.125 g) every 24 hours after the day 1 loading dose

Source ID

H51-5299D5D3F9E733F9E93C38A1

Pediatric dosing range

Not established in the currently normalized record. Use the current-label panel before clinical use.

Source ID

H51-4E192A887A762883D39F603B

Neonatal dosing range

Not established in the currently normalized record. Use the current-label panel before clinical use.

Source ID

H51-5A4817576C2A0BFF789B25EC

Infusion time

Infuse over 4 hours Infuse over 2 hours

Source ID

H51-EB8C4E26BFC1F4A45842791C

Fluid restriction alternatives

Not established in the currently normalized record. Use the current-label panel before clinical use.

Source ID

H51-71D4D064D78D66D382D1B252

Current manufacturer labeling

Match confidence: unresolved
Source ID
H51-D6D36E5C3BD5212BFF6A74E7
Url: https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Cefepime-enmetazobactam (opens in a new tab)
Source ID
H51-D6674263EE618B7A6A3D7A1E

Field provenance

Exact formulation

Primary: existing_record_text
Source ID
H51-899DA0DE1DCE77D47714197D

Reconstitution concentration

Primary: existing_structured_record
Source ID
H51-3E2756E39D1FB83FECC81DF0

Maximum or recommended final concentration

Primary: existing_record_text
Source ID
H51-EC1E8B31A31079475AD61F7C

Appropriate standardized containers

Primary: existing_structured_record
Source ID
H51-A42476AB25AF7C3203FFFEAE

Adult dosing range

Primary: existing_structured_record
Source ID
H51-351E59FD40B003DDE8AF6AB6

Pediatric dosing range

Primary: not_found
Source ID
H51-27349557128DC0D6425C2A40

Neonatal dosing range

Primary: not_found
Source ID
H51-3B64BB3029C22797056B1F5E

Infusion time

Primary: existing_structured_record
Source ID
H51-3DFE789C2F23F3130C346B9B

Fluid restriction alternatives

Primary: not_found
Source ID
H51-7272DB92F1127F8F38A84C19

Current manufacturer labeling

Primary: DailyMed search gateway
Source ID
H51-ACA7A76CDCDC035ADB21A5F2

Population applicability

Adult

Applicability: supported_or_source_present
Source ID
H51-DFF4364C4DAA5C39420CA1BC
Guide generation allowed: true
Source ID
H51-2B541ED2B708540FBDD27C62

Pediatric

Applicability: supported_or_source_present
Source ID
H51-535376DEF835B48CFEA59C2E
Guide generation allowed: false
Source ID
H51-5ABC4825F17ADE5B913B3804

Neonatal

Applicability: supported_or_source_present
Source ID
H51-5EF0CE2C1E12207E29315A97
Guide generation allowed: false
Source ID
H51-5B816986B3DB0E6513D4C504

Route presence

Structured dilution: true
Source ID
H51-DFAF4CE8D3BC3B852C4A75E5
Iv push: false
Source ID
H51-3226EE5CF4EFE2C51DEA84A8
Continuous infusion: false
Source ID
H51-35842DAA1A21CFB9AACF4401
Pediatric source: true
Source ID
H51-A6BDE781A7918A46E1B4F8BF
Neonatal source: true
Source ID
H51-E61A086684524653F03DB886

Legacy reference

Status: not_available
Source ID
H51-96275E048E0E4B458B9D0CE4

Label resolution

Status: build_environment_network_unavailable
Source ID
H51-F2040E832223CFBC6687B07E

Concentration values detected

High	Unit	Text
Source ID `H51-0FA193FE1C0F68FD6FB20602` 10 Source ID `H51-A43E381EF5019B1FF1F819D6`	mg Source ID `H51-EBFB76D5E11232FC17072E13`	10 mg/mL Source ID `H51-AED65E6BD265ACB71DB8F7E9`
Source ID `H51-767FF0E746CAAD9714E9F209` 10 Source ID `H51-5496516B585BC1D16F39BF37`	mg Source ID `H51-259195B4096C59232D806EAA`	10 mg/mL Source ID `H51-48D677EF1CDFE66FF3674810`
Source ID `H51-1A7FE3A8E1EF6EEB603A493E` 10 Source ID `H51-BF2C331D85FE937A4352743F`	mg Source ID `H51-9E2471C8324E08408D1454F8`	10 mg/mL Source ID `H51-EE42E54DCF1151941F5B9FC2`
Source ID `H51-66A2BEB83C7CA476E52E7F67` 5 Source ID `H51-8E35B8C97A93C2E37EB19219`	mg Source ID `H51-EF60A5107DFCEF9468A4EF3C`	5 mg/mL Source ID `H51-FD3F89FFC8F6BEAD1A0E4C04`
Source ID `H51-A1C879824298F24A6A5ABE6F` 5 Source ID `H51-01E6EF6803321F074B724014`	mg Source ID `H51-302FB2753E20759B098038F9`	5 mg/mL Source ID `H51-735DE0A7AE75A86991AB7723`

Source files

catalog.json
Source ID
H51-7ED657A1EBA5C20C8044BDF0
dosing.json
Source ID
H51-7E0002B607542072F8B10D03
new-in-v1.2.json
Source ID
H51-B5BAF62D15B1BB492E10C247
new-in-v1.3.json
Source ID
H51-7C58E7ACC6C1E7D1DDF9D6E3

Clinical release note

Preparation instructions are released only at the evidence level shown. Legacy content remains visibly separate. Exact product, NDC, route, current labeling, and institutional policy must be confirmed.

Source ID

H51-A95AB7946F5C8FE8801CDE6A

Historical statement IDs and source locations

These IDs identify recovered source units. They are not evidence-qualified clinical claims.

Historical ID	Original source location	Status
`H51-46EB92497506B74D51402FCD`	catalog.json `/records/44/id`	Historical; current review incomplete
`H51-F49C0CBA6634C6E5D9C26355`	catalog.json `/records/44/generic_name`	Historical; current review incomplete
`H51-276940F4CC87ABD001F0A943`	catalog.json `/records/44/brand_names/0`	Historical; current review incomplete
`H51-708FA9719A4FAA9F0720FE58`	catalog.json `/records/44/aliases/0`	Historical; current review incomplete
`H51-E3AB3B1F00B618F44A837C03`	catalog.json `/records/44/class`	Historical; current review incomplete
`H51-265F06C371E911BBE622CC52`	catalog.json `/records/44/subclass`	Historical; current review incomplete
`H51-91A22AB8AC71156B422A9F00`	catalog.json `/records/44/summary`	Historical; current review incomplete
`H51-2996803C045A63D8EC326913`	catalog.json `/records/44/common_uses/0`	Historical; current review incomplete
`H51-74F6193CA6F4393F211716FF`	catalog.json `/records/44/common_uses/1`	Historical; current review incomplete
`H51-D196E903D1F068F1925A97C4`	catalog.json `/records/44/preparations/0`	Historical; current review incomplete
`H51-4BA3CAE4DE1EAA2C78885CC0`	catalog.json `/records/44/preparations/0/population`	Historical; current review incomplete
`H51-6E5BE1BD0074139E07A8003D`	catalog.json `/records/44/preparations/0/amount`	Historical; current review incomplete
`H51-97271438D1B299C9564DF754`	catalog.json `/records/44/preparations/0/reconstitution`	Historical; current review incomplete
`H51-39AF97B6B18610F84539AAD8`	catalog.json `/records/44/preparations/0/diluent`	Historical; current review incomplete
`H51-76D7186981C9A82A18435DF7`	catalog.json `/records/44/preparations/0/final_volume`	Historical; current review incomplete
`H51-53FDC3A1338547646E244FE9`	catalog.json `/records/44/preparations/0/concentration`	Historical; current review incomplete
`H51-4A672707B818C7D5F4E5D493`	catalog.json `/records/44/preparations/0/rate`	Historical; current review incomplete
`H51-325EC2C61F297EBE02F5BD9D`	catalog.json `/records/44/preparations/0/stability`	Historical; current review incomplete
`H51-2849B41DE527DEDC7D7253FF`	catalog.json `/records/44/preparations/0/notes`	Historical; current review incomplete
`H51-8C0F90196D087B71AC03C226`	catalog.json `/records/44/preparations/1`	Historical; current review incomplete
`H51-8DACC3A78539A68E282A35CD`	catalog.json `/records/44/preparations/1/population`	Historical; current review incomplete
`H51-48C8AB8206085031295FA6A7`	catalog.json `/records/44/preparations/1/amount`	Historical; current review incomplete
`H51-3AF13EA417EDAC398550D0C9`	catalog.json `/records/44/preparations/1/reconstitution`	Historical; current review incomplete
`H51-C739E115EF4B32E75EBB827B`	catalog.json `/records/44/preparations/1/diluent`	Historical; current review incomplete
`H51-C53E1E98A3AEDD09DE33633E`	catalog.json `/records/44/preparations/1/final_volume`	Historical; current review incomplete
`H51-0F9DD05F9FA20A5155854B88`	catalog.json `/records/44/preparations/1/concentration`	Historical; current review incomplete
`H51-FBFFAA65C8C443C4893FB320`	catalog.json `/records/44/preparations/1/rate`	Historical; current review incomplete
`H51-8C053E00C8878E24DBEC9385`	catalog.json `/records/44/preparations/1/stability`	Historical; current review incomplete
`H51-AD661037F00E0E7A78F4F53C`	catalog.json `/records/44/preparations/1/notes`	Historical; current review incomplete
`H51-323651D699D0EE812E4B9E39`	catalog.json `/records/44/preparations/2`	Historical; current review incomplete
`H51-6EE1CD75030B17E26D7FB59C`	catalog.json `/records/44/preparations/2/population`	Historical; current review incomplete
`H51-97D119FEB63310F57915690F`	catalog.json `/records/44/preparations/2/amount`	Historical; current review incomplete
`H51-AD47895B840E53ED325963D3`	catalog.json `/records/44/preparations/2/reconstitution`	Historical; current review incomplete
`H51-EDEF60A813865A84C600A1F7`	catalog.json `/records/44/preparations/2/diluent`	Historical; current review incomplete
`H51-601EDE570900603541A900F6`	catalog.json `/records/44/preparations/2/final_volume`	Historical; current review incomplete
`H51-D5DA8133151CD58E842ABED3`	catalog.json `/records/44/preparations/2/concentration`	Historical; current review incomplete
`H51-ECE5FA3C1FBE4FC567069270`	catalog.json `/records/44/preparations/2/rate`	Historical; current review incomplete
`H51-78B34AAADA105C07ADD578F5`	catalog.json `/records/44/preparations/2/stability`	Historical; current review incomplete
`H51-AF91120DDCF7608FD8CE947C`	catalog.json `/records/44/preparations/2/notes`	Historical; current review incomplete
`H51-5A781E30EF29A81D8C9CA51D`	catalog.json `/records/44/preparations/3`	Historical; current review incomplete
`H51-118E4D90656CE0087B5EF9F8`	catalog.json `/records/44/preparations/3/population`	Historical; current review incomplete
`H51-AF9FA542E797464CD0F965A0`	catalog.json `/records/44/preparations/3/amount`	Historical; current review incomplete
`H51-3BFDD781E1C80151429EF30E`	catalog.json `/records/44/preparations/3/reconstitution`	Historical; current review incomplete
`H51-A9F1F8ADB56C2FBDE6F9575F`	catalog.json `/records/44/preparations/3/diluent`	Historical; current review incomplete
`H51-463D1195D494F8CFF55AD072`	catalog.json `/records/44/preparations/3/final_volume`	Historical; current review incomplete
`H51-003EFB8588AFAFED1C7AED18`	catalog.json `/records/44/preparations/3/concentration`	Historical; current review incomplete
`H51-658ADF37E7D1B1CD3D5C060F`	catalog.json `/records/44/preparations/3/rate`	Historical; current review incomplete
`H51-8EB0C35BDAAA191E65A89A73`	catalog.json `/records/44/preparations/3/stability`	Historical; current review incomplete
`H51-69685019FDF3B28A42E07440`	catalog.json `/records/44/preparations/3/notes`	Historical; current review incomplete
`H51-71509B7B7AB96E24A8868E07`	catalog.json `/records/44/preparations/4`	Historical; current review incomplete
`H51-71931975FF12B9937AE12B9C`	catalog.json `/records/44/preparations/4/population`	Historical; current review incomplete
`H51-8064DF2509C7433D74D6F9FD`	catalog.json `/records/44/preparations/4/amount`	Historical; current review incomplete
`H51-960E8CAE61D05AD7AFC11DF5`	catalog.json `/records/44/preparations/4/reconstitution`	Historical; current review incomplete
`H51-F84C3311048C781F1B70F3F7`	catalog.json `/records/44/preparations/4/diluent`	Historical; current review incomplete
`H51-A708E40BF88304F4FFD85C5A`	catalog.json `/records/44/preparations/4/final_volume`	Historical; current review incomplete
`H51-44E970161B71822BFBDB1424`	catalog.json `/records/44/preparations/4/concentration`	Historical; current review incomplete
`H51-B401F472B75A687EEDEF2B2E`	catalog.json `/records/44/preparations/4/rate`	Historical; current review incomplete
`H51-F1AC441C3F7FF6BD442D66D2`	catalog.json `/records/44/preparations/4/stability`	Historical; current review incomplete
`H51-2A1310D3820699B3F3E708DC`	catalog.json `/records/44/preparations/4/notes`	Historical; current review incomplete
`H51-D14B7CE8053984F69442E4B2`	catalog.json `/records/44/preparations/5`	Historical; current review incomplete
`H51-467E6F649E5ACFD85C63BCEB`	catalog.json `/records/44/preparations/5/population`	Historical; current review incomplete
`H51-D0D4C18BA42D6A13F64AB0AC`	catalog.json `/records/44/preparations/5/amount`	Historical; current review incomplete
`H51-200963F2DFE98D5A04C0C69C`	catalog.json `/records/44/preparations/5/reconstitution`	Historical; current review incomplete
`H51-F2CC831D6E34FAA320732E1D`	catalog.json `/records/44/preparations/5/diluent`	Historical; current review incomplete
`H51-6E5928D8F3DD8F063A82E168`	catalog.json `/records/44/preparations/5/final_volume`	Historical; current review incomplete
`H51-6401275A7C5ADEE07DC0E700`	catalog.json `/records/44/preparations/5/concentration`	Historical; current review incomplete
`H51-3246A90E56A1BB1BD4659755`	catalog.json `/records/44/preparations/5/rate`	Historical; current review incomplete
`H51-3F7F4035F394FDCE871FD183`	catalog.json `/records/44/preparations/5/stability`	Historical; current review incomplete
`H51-0C6BF4F33A4B9DE45550B77B`	catalog.json `/records/44/preparations/5/notes`	Historical; current review incomplete
`H51-B755D14F53D6F4F096D2A14B`	catalog.json `/records/44/preparations/6`	Historical; current review incomplete
`H51-038974CB4DC5BA78BF36B92A`	catalog.json `/records/44/preparations/6/population`	Historical; current review incomplete
`H51-2BF3A14659386DC6816C179E`	catalog.json `/records/44/preparations/6/amount`	Historical; current review incomplete
`H51-5E8CC2C0D0D8FDCC864B1D85`	catalog.json `/records/44/preparations/6/reconstitution`	Historical; current review incomplete
`H51-8250B696048EDF32FA2F18A1`	catalog.json `/records/44/preparations/6/diluent`	Historical; current review incomplete
`H51-F37AB76B3842CD69FD7846EE`	catalog.json `/records/44/preparations/6/final_volume`	Historical; current review incomplete
`H51-CDF1AB822BAFADD7E8F71BFF`	catalog.json `/records/44/preparations/6/concentration`	Historical; current review incomplete
`H51-30B686C3E5C322087EF785A3`	catalog.json `/records/44/preparations/6/rate`	Historical; current review incomplete
`H51-C81FA0392A89498C804A1395`	catalog.json `/records/44/preparations/6/stability`	Historical; current review incomplete
`H51-7DBE25D53BA7F12CDE398DB6`	catalog.json `/records/44/preparations/6/notes`	Historical; current review incomplete
`H51-7DF9490C480A14F96F409D7E`	catalog.json `/records/44/warnings/0`	Historical; current review incomplete
`H51-7F4DB032BF46117AF82B5E0D`	catalog.json `/records/44/warnings/1`	Historical; current review incomplete
`H51-57133BC4DDA6DCB04E3C3647`	catalog.json `/records/44/warnings/2`	Historical; current review incomplete
`H51-1432350FD9333BA1FC2C6FC3`	catalog.json `/records/44/warnings/3`	Historical; current review incomplete
`H51-F48DFDD8363DEE35C70FA32D`	catalog.json `/records/44/warnings/4`	Historical; current review incomplete
`H51-32F65B0BC59FDE344C33E4D4`	catalog.json `/records/44/monitoring/0`	Historical; current review incomplete
`H51-814AFE9A1FC4CE9AE110A46A`	catalog.json `/records/44/monitoring/1`	Historical; current review incomplete
`H51-4B3CDBDA465ED5BC6D04FC81`	catalog.json `/records/44/monitoring/2`	Historical; current review incomplete
`H51-8C5DAD38A5A477195455EA9C`	catalog.json `/records/44/monitoring/3`	Historical; current review incomplete
`H51-A3260A06EBBEA694C012581A`	catalog.json `/records/44/monitoring/4`	Historical; current review incomplete
`H51-45DC213DF6608B408724144B`	catalog.json `/records/44/monitoring/5`	Historical; current review incomplete
`H51-96965FA7B79269B0AB0B9D1B`	catalog.json `/records/44/compatibility/0`	Historical; current review incomplete
`H51-86E859AB54A41F0FA9D2B2D9`	catalog.json `/records/44/compatibility/1`	Historical; current review incomplete
`H51-38FCE6F318CFE5B47D188029`	catalog.json `/records/44/compatibility/2`	Historical; current review incomplete
`H51-DBF37CAEDE65827C83E6A26A`	catalog.json `/records/44/stability_notes/0`	Historical; current review incomplete
`H51-36BDAFA8839874363E813FD2`	catalog.json `/records/44/stability_notes/1`	Historical; current review incomplete
`H51-2AE8020D9D22E7F36CF15E3F`	catalog.json `/records/44/stability_notes/2`	Historical; current review incomplete
`H51-38C7E76A01BDFBE00180C95C`	catalog.json `/records/44/stability_notes/3`	Historical; current review incomplete
`H51-7F5CDB53D1108B230D3FB162`	catalog.json `/records/44/populations/0`	Historical; current review incomplete
`H51-8FFC8A2E617FCB175126954E`	catalog.json `/records/44/populations/1`	Historical; current review incomplete
`H51-4AC8B9472D50CA3310616BB9`	catalog.json `/records/44/populations/2`	Historical; current review incomplete
`H51-2B547F1549342AC7A7D57B52`	catalog.json `/records/44/evidence_tier`	Historical; current review incomplete
`H51-84408EBF689BF7A3ADA4C819`	catalog.json `/records/44/high_alert`	Historical; current review incomplete
`H51-9A333A437A202065F03C12F3`	catalog.json `/records/44/hazardous`	Historical; current review incomplete
`H51-503D78AE9E06C6D722988E23`	catalog.json `/records/44/status`	Historical; current review incomplete
`H51-EF29C28F5783A3FC581A29B6`	catalog.json `/records/44/reviewed`	Historical; current review incomplete
`H51-7D956356D3881E7936A40292`	catalog.json `/records/44/version_added`	Historical; current review incomplete
`H51-BCB71E9AE7A2A34B849E4D3B`	catalog.json `/records/44/version_updated`	Historical; current review incomplete
`H51-A2D7B8C06B1869216F4C91B5`	catalog.json `/records/44/sources/0`	Historical; current review incomplete
`H51-B2CB5FCD16AFF8B972A92E4E`	catalog.json `/records/44/sources/0/label`	Historical; current review incomplete
`H51-2681BA71C13608180679EB27`	catalog.json `/records/44/sources/0/url`	Historical; current review incomplete
`H51-D1F2D7965FA78F0A5280720F`	catalog.json `/records/44/sources/0/kind`	Historical; current review incomplete
`H51-481400DAD7BF0F589D66013D`	catalog.json `/records/44/sources/1`	Historical; current review incomplete
`H51-637E6C8DDFE7310661A2E558`	catalog.json `/records/44/sources/1/label`	Historical; current review incomplete
`H51-E2EFE8603E158F813A3D63A8`	catalog.json `/records/44/sources/1/url`	Historical; current review incomplete
`H51-BDBEB77E3400B2C1A44385E0`	catalog.json `/records/44/sources/1/kind`	Historical; current review incomplete
`H51-FC77B96C8EC3E4538D0E1EC5`	catalog.json `/records/44/legacy_title`	Historical; current review incomplete
`H51-6A812AAD7EE3BA9EB3CF0FC1`	catalog.json `/records/44/clinical_release_verification/audit_version`	Historical; current review incomplete
`H51-4BCE6FA778EDFCFB8696DD0B`	catalog.json `/records/44/clinical_release_verification/audited_on`	Historical; current review incomplete
`H51-D253CE70F551AFE9D13EBA4D`	catalog.json `/records/44/clinical_release_verification/level`	Historical; current review incomplete
`H51-54A75AF25C67E4243E63403F`	catalog.json `/records/44/clinical_release_verification/release_gate`	Historical; current review incomplete
`H51-13DC94D6086E9231D66FF494`	catalog.json `/records/44/clinical_release_verification/exact_current_label_candidate`	Historical; current review incomplete
`H51-7FE269A0CC223AE9CB1A5A79`	catalog.json `/records/44/clinical_release_verification/selected_setid`	Historical; current review incomplete
`H51-7BBF834C0D53A3CC5265BC6C`	catalog.json `/records/44/clinical_release_verification/selected_label_title`	Historical; current review incomplete
`H51-299A7DCDAE97A236E428A2B8`	catalog.json `/records/44/clinical_release_verification/numeric_support_ratio`	Historical; current review incomplete
`H51-BC20F6981681DA0C84FAE168`	catalog.json `/records/44/clinical_release_verification/reference_url_count`	Historical; current review incomplete
`H51-653788941C60CFB1A72F78CB`	catalog.json `/records/44/clinical_release_verification/broken_reference_count`	Historical; current review incomplete
`H51-A22B0D9695A7D0A35373B7E0`	catalog.json `/records/44/clinical_release_verification/point_of_use_confirmation_required`	Historical; current review incomplete
`H51-BC22D4166245BAFC309A0EE0`	catalog.json `/records/44/clinical_release_verification/note`	Historical; current review incomplete
`H51-8DB15192071EF621568B0F93`	catalog.json `/records/44/clinical_release_verification/dailymed_search_url`	Historical; current review incomplete
`H51-EECB65B75CE753EF7BA479B7`	dosing.json `/records/44/id`	Historical; current review incomplete
`H51-59EBEE32D757C99BD17FC4F1`	dosing.json `/records/44/generic_name`	Historical; current review incomplete
`H51-15F962620A951F2B578250F0`	dosing.json `/records/44/coverage_status`	Historical; current review incomplete
`H51-98779493A7CA6A2403CE1042`	dosing.json `/records/44/package_insert/query_name`	Historical; current review incomplete
`H51-9FE53F10FB19B7927DAFE488`	dosing.json `/records/44/package_insert/preferred_setid`	Historical; current review incomplete
`H51-5A958FAFC7696605F738E368`	dosing.json `/records/44/package_insert/product_and_route_must_match`	Historical; current review incomplete
`H51-C7B64CC3061AC0F95B8D81BE`	dosing.json `/records/44/package_insert/live_current_label_enabled`	Historical; current review incomplete
`H51-38B18947FAE8F9DEA98A3445`	dosing.json `/records/44/package_insert/source_priority`	Historical; current review incomplete
`H51-AA7A39D2E57BB7958F233654`	dosing.json `/records/44/package_insert/direct_official_label_access_enabled`	Historical; current review incomplete
`H51-9EF3C5386C5616D7A71AD88F`	dosing.json `/records/44/package_insert/outbound_server_request_required`	Historical; current review incomplete
`H51-8B1AECADCDDFCE187B14467A`	dosing.json `/records/44/package_insert/local_summary_status`	Historical; current review incomplete
`H51-F2B4BC28937F41F72A65090C`	dosing.json `/records/44/renal/classification`	Historical; current review incomplete
`H51-32879C3BA0FC61EE8487CA59`	dosing.json `/records/44/renal/summary`	Historical; current review incomplete
`H51-D30DFAFD002C47EA1699E31D`	dosing.json `/records/44/renal/method_note`	Historical; current review incomplete
`H51-9F72130096C0AAA9E90B42B2`	dosing.json `/records/44/existing_route_snapshots/0`	Historical; current review incomplete
`H51-8ACBC4CDCE4E8C82BC8D7009`	dosing.json `/records/44/existing_route_snapshots/0/route`	Historical; current review incomplete
`H51-5316329AB1D3EDB832A9E400`	dosing.json `/records/44/existing_route_snapshots/0/population`	Historical; current review incomplete
`H51-CE594B04A950C91026695A63`	dosing.json `/records/44/existing_route_snapshots/0/indication`	Historical; current review incomplete
`H51-D54B38C2D5C23BB701E8D829`	dosing.json `/records/44/existing_route_snapshots/0/dose`	Historical; current review incomplete
`H51-21B93F309C7015674A798A72`	dosing.json `/records/44/existing_route_snapshots/0/interval`	Historical; current review incomplete
`H51-6CF2E535FA078ADDD0786B01`	dosing.json `/records/44/existing_route_snapshots/0/duration`	Historical; current review incomplete
`H51-EE3EB8DA4B6F3207302E8DD4`	dosing.json `/records/44/existing_route_snapshots/0/administration`	Historical; current review incomplete
`H51-C434E22F58DD11AF838ADFCB`	dosing.json `/records/44/existing_route_snapshots/0/source_level`	Historical; current review incomplete
`H51-FFD7A27ED6B99611C4E5DC7F`	dosing.json `/records/44/existing_route_snapshots/0/notes`	Historical; current review incomplete
`H51-BC36A6C2B3D9F229759A8C15`	dosing.json `/records/44/existing_route_snapshots/1`	Historical; current review incomplete
`H51-AD67F836A58A26625EB1F65F`	dosing.json `/records/44/existing_route_snapshots/1/route`	Historical; current review incomplete
`H51-BA0B3BA4ADC229735EAEC7BD`	dosing.json `/records/44/existing_route_snapshots/1/population`	Historical; current review incomplete
`H51-2E087C9F18EF3CC536518513`	dosing.json `/records/44/existing_route_snapshots/1/indication`	Historical; current review incomplete
`H51-7544CF088E51D89329AC61CB`	dosing.json `/records/44/existing_route_snapshots/1/dose`	Historical; current review incomplete
`H51-A445F0537F0684A392A3AB90`	dosing.json `/records/44/existing_route_snapshots/1/interval`	Historical; current review incomplete
`H51-D8CAF0C7657BFD8F44D12AF0`	dosing.json `/records/44/existing_route_snapshots/1/duration`	Historical; current review incomplete
`H51-0599FB426E25B91DA14D3BBB`	dosing.json `/records/44/existing_route_snapshots/1/administration`	Historical; current review incomplete
`H51-2A583F71D4EE5AE0ACC1BEB3`	dosing.json `/records/44/existing_route_snapshots/1/source_level`	Historical; current review incomplete
`H51-5C5C24A051B084EE6B1EE595`	dosing.json `/records/44/existing_route_snapshots/1/notes`	Historical; current review incomplete
`H51-3B089FAD85DDDD53B10AA104`	dosing.json `/records/44/existing_route_snapshots/2`	Historical; current review incomplete
`H51-1966B997BACC4B97F616A722`	dosing.json `/records/44/existing_route_snapshots/2/route`	Historical; current review incomplete
`H51-8591039AB70253A22460F202`	dosing.json `/records/44/existing_route_snapshots/2/population`	Historical; current review incomplete
`H51-69633B18C9C5BCB712F11A8C`	dosing.json `/records/44/existing_route_snapshots/2/indication`	Historical; current review incomplete
`H51-5C71DB7F2B93A9841CAA7234`	dosing.json `/records/44/existing_route_snapshots/2/dose`	Historical; current review incomplete
`H51-FEE0BD9DC4CBB40CA5655F20`	dosing.json `/records/44/existing_route_snapshots/2/interval`	Historical; current review incomplete
`H51-77CB744F188E2ADB90951488`	dosing.json `/records/44/existing_route_snapshots/2/duration`	Historical; current review incomplete
`H51-8249BAA1A6087E676356C809`	dosing.json `/records/44/existing_route_snapshots/2/administration`	Historical; current review incomplete
`H51-4550EFD5067A5BF9C9EE746E`	dosing.json `/records/44/existing_route_snapshots/2/source_level`	Historical; current review incomplete
`H51-7AECB625F695F716A8988606`	dosing.json `/records/44/existing_route_snapshots/2/notes`	Historical; current review incomplete
`H51-3DB86E3B025F1DB8BF07D37F`	dosing.json `/records/44/existing_route_snapshots/3`	Historical; current review incomplete
`H51-5FB80CA33B9BB52DC1B57A0C`	dosing.json `/records/44/existing_route_snapshots/3/route`	Historical; current review incomplete
`H51-9EAD519DA507A1C8D4E1198A`	dosing.json `/records/44/existing_route_snapshots/3/population`	Historical; current review incomplete
`H51-3D58D857D4B3A70B7F094961`	dosing.json `/records/44/existing_route_snapshots/3/indication`	Historical; current review incomplete
`H51-0997B119ED48EE87695C3B35`	dosing.json `/records/44/existing_route_snapshots/3/dose`	Historical; current review incomplete
`H51-6FA1688AC9F9877583B0B41C`	dosing.json `/records/44/existing_route_snapshots/3/interval`	Historical; current review incomplete
`H51-C7405B915EAB7FAC692D1D5B`	dosing.json `/records/44/existing_route_snapshots/3/duration`	Historical; current review incomplete
`H51-5E35EBBFD13CAC16FE87B953`	dosing.json `/records/44/existing_route_snapshots/3/administration`	Historical; current review incomplete
`H51-51CC3922F040B55A962BBF4E`	dosing.json `/records/44/existing_route_snapshots/3/source_level`	Historical; current review incomplete
`H51-7B1D9F3BCCFDAED71BD2915F`	dosing.json `/records/44/existing_route_snapshots/3/notes`	Historical; current review incomplete
`H51-B1E9D55B87DCA3EBDD6EC96F`	dosing.json `/records/44/existing_route_snapshots/4`	Historical; current review incomplete
`H51-BD1849EC746CBDC3E1CA53EA`	dosing.json `/records/44/existing_route_snapshots/4/route`	Historical; current review incomplete
`H51-7726D8BDB9EF8C6D1B21ECE3`	dosing.json `/records/44/existing_route_snapshots/4/population`	Historical; current review incomplete
`H51-6A27D91150FFC10BBBC44089`	dosing.json `/records/44/existing_route_snapshots/4/indication`	Historical; current review incomplete
`H51-492D2E689AF1C7BE4418457D`	dosing.json `/records/44/existing_route_snapshots/4/dose`	Historical; current review incomplete
`H51-EAC3D7606767B1CC68DF9474`	dosing.json `/records/44/existing_route_snapshots/4/interval`	Historical; current review incomplete
`H51-E52036DB004BE873FA2A3B31`	dosing.json `/records/44/existing_route_snapshots/4/duration`	Historical; current review incomplete
`H51-D13FCE8233717AD482D1690C`	dosing.json `/records/44/existing_route_snapshots/4/administration`	Historical; current review incomplete
`H51-3447A8DA589FD573204D5A13`	dosing.json `/records/44/existing_route_snapshots/4/source_level`	Historical; current review incomplete
`H51-8D34B47623F9BBA6D0F44F17`	dosing.json `/records/44/existing_route_snapshots/4/notes`	Historical; current review incomplete
`H51-B0DE2B72D5102091261069FD`	dosing.json `/records/44/existing_route_snapshots/5`	Historical; current review incomplete
`H51-D095D62B67BCC90A7489EED6`	dosing.json `/records/44/existing_route_snapshots/5/route`	Historical; current review incomplete
`H51-9A031E5FB04AABDE7F03D4DC`	dosing.json `/records/44/existing_route_snapshots/5/population`	Historical; current review incomplete
`H51-51A989B0501BE33C31710DAB`	dosing.json `/records/44/existing_route_snapshots/5/indication`	Historical; current review incomplete
`H51-B95E22FF43F60611A410718D`	dosing.json `/records/44/existing_route_snapshots/5/dose`	Historical; current review incomplete
`H51-1CBEED715CF8A380CE18CBC8`	dosing.json `/records/44/existing_route_snapshots/5/interval`	Historical; current review incomplete
`H51-39309D304BD13885FD424EA2`	dosing.json `/records/44/existing_route_snapshots/5/duration`	Historical; current review incomplete
`H51-60268302780A0618EFC7A3C5`	dosing.json `/records/44/existing_route_snapshots/5/administration`	Historical; current review incomplete
`H51-63135ADB46A1C437AF37AAC4`	dosing.json `/records/44/existing_route_snapshots/5/source_level`	Historical; current review incomplete
`H51-4B81FF0827571A5132A26E76`	dosing.json `/records/44/existing_route_snapshots/5/notes`	Historical; current review incomplete
`H51-2A22FC4FD11C65FA34D33BA5`	dosing.json `/records/44/existing_route_snapshots/6`	Historical; current review incomplete
`H51-5EB401B8D6B413B73EED8018`	dosing.json `/records/44/existing_route_snapshots/6/route`	Historical; current review incomplete
`H51-2A973A522840CE0AC0BEA052`	dosing.json `/records/44/existing_route_snapshots/6/population`	Historical; current review incomplete
`H51-B918BAD928938E208190D9E1`	dosing.json `/records/44/existing_route_snapshots/6/indication`	Historical; current review incomplete
`H51-32BBEF777B11823C71AC5714`	dosing.json `/records/44/existing_route_snapshots/6/dose`	Historical; current review incomplete
`H51-16A1EA876C0FFB45ACDAA320`	dosing.json `/records/44/existing_route_snapshots/6/interval`	Historical; current review incomplete
`H51-770AC4527EDC7B2B762F2A30`	dosing.json `/records/44/existing_route_snapshots/6/duration`	Historical; current review incomplete
`H51-92DB9971916A99657355FC35`	dosing.json `/records/44/existing_route_snapshots/6/administration`	Historical; current review incomplete
`H51-0994A2448A5D17EEA4588D01`	dosing.json `/records/44/existing_route_snapshots/6/source_level`	Historical; current review incomplete
`H51-36AC0B0DB25B96A56BEEA93F`	dosing.json `/records/44/existing_route_snapshots/6/notes`	Historical; current review incomplete
`H51-58042A72B369425C41F51A55`	dosing.json `/records/44/professional_sources/0`	Historical; current review incomplete
`H51-89F6F0DC2E03C1C9FAFAE2D3`	dosing.json `/records/44/professional_sources/0/label`	Historical; current review incomplete
`H51-F83D2910C7BEB7AE3F1D885B`	dosing.json `/records/44/professional_sources/0/url`	Historical; current review incomplete
`H51-A7E24F6163A389D3CCF259D9`	dosing.json `/records/44/professional_sources/0/kind`	Historical; current review incomplete
`H51-667DDB0FB655FE20462B878A`	dosing.json `/records/44/professional_sources/1`	Historical; current review incomplete
`H51-E5E1EE59F28DEAE3B7A2F1B1`	dosing.json `/records/44/professional_sources/1/label`	Historical; current review incomplete
`H51-D765765B40766F5A13F4090C`	dosing.json `/records/44/professional_sources/1/url`	Historical; current review incomplete
`H51-3F410F1043B7EF867B7A8BB0`	dosing.json `/records/44/professional_sources/1/kind`	Historical; current review incomplete
`H51-37486DF66AE06227ED4A2C9C`	dosing.json `/records/44/professional_sources/2`	Historical; current review incomplete
`H51-0DB22ED4407FBA70925DD143`	dosing.json `/records/44/professional_sources/2/label`	Historical; current review incomplete
`H51-C1827080793AF81180C26405`	dosing.json `/records/44/professional_sources/2/url`	Historical; current review incomplete
`H51-B6C7FF31800707759219B3C6`	dosing.json `/records/44/professional_sources/2/kind`	Historical; current review incomplete
`H51-B74E4ACFB4F51CAF7FE57CB3`	dosing.json `/records/44/professional_sources/3`	Historical; current review incomplete
`H51-8DF8E1AE9B97CB701412E075`	dosing.json `/records/44/professional_sources/3/label`	Historical; current review incomplete
`H51-3A29A44C99361D2A91A9F7FB`	dosing.json `/records/44/professional_sources/3/url`	Historical; current review incomplete
`H51-8CBD5B21C1054113A9D6901E`	dosing.json `/records/44/professional_sources/3/kind`	Historical; current review incomplete
`H51-1C48A7F002688EA43F746185`	dosing.json `/records/44/clinical_review/locally_normalized`	Historical; current review incomplete
`H51-C4B7E9C105E2105DFFD436A2`	dosing.json `/records/44/clinical_review/reviewed`	Historical; current review incomplete
`H51-28CAA1BEAF9FA4605351CD5E`	dosing.json `/records/44/clinical_review/status`	Historical; current review incomplete
`H51-4579819D41F9779464F03B16`	dosing.json `/records/44/clinical_release_verification/audit_version`	Historical; current review incomplete
`H51-0470C4CDB96C9EB85A17B54B`	dosing.json `/records/44/clinical_release_verification/audited_on`	Historical; current review incomplete
`H51-5C0643BDFB92E0777DB3B7DB`	dosing.json `/records/44/clinical_release_verification/level`	Historical; current review incomplete
`H51-54CBA48A3B18B647C369B2DF`	dosing.json `/records/44/clinical_release_verification/release_gate`	Historical; current review incomplete
`H51-A9A56937D5486CB65EA21F97`	dosing.json `/records/44/clinical_release_verification/exact_current_label_candidate`	Historical; current review incomplete
`H51-961FBC95853E6C4057954D42`	dosing.json `/records/44/clinical_release_verification/selected_setid`	Historical; current review incomplete
`H51-F7090275A3593B1E64843EEF`	dosing.json `/records/44/clinical_release_verification/selected_label_title`	Historical; current review incomplete
`H51-2C794906157C1E393D174E3D`	dosing.json `/records/44/clinical_release_verification/numeric_support_ratio`	Historical; current review incomplete
`H51-A626A40B88B8BC29814881BB`	dosing.json `/records/44/clinical_release_verification/reference_url_count`	Historical; current review incomplete
`H51-528E1732D9908DD78ECBB427`	dosing.json `/records/44/clinical_release_verification/broken_reference_count`	Historical; current review incomplete
`H51-19BEE3F6420BE6EBC958E714`	dosing.json `/records/44/clinical_release_verification/point_of_use_confirmation_required`	Historical; current review incomplete
`H51-54EF86654C58113AE7B626AA`	dosing.json `/records/44/clinical_release_verification/note`	Historical; current review incomplete
`H51-42509450A270397167D013C8`	dosing.json `/records/44/clinical_release_verification/dailymed_search_url`	Historical; current review incomplete
`H51-AE8233083D1A0473EB6C5871`	first-look-v5.1.json `/records/44/id`	Historical; current review incomplete
`H51-261A20DA03D25F29F28F32DC`	first-look-v5.1.json `/records/44/generic_name`	Historical; current review incomplete
`H51-E330C4DAB9F52D2D0C20C89A`	first-look-v5.1.json `/records/44/class`	Historical; current review incomplete
`H51-4FF0EF4417FF09657DD962A4`	first-look-v5.1.json `/records/44/subclass`	Historical; current review incomplete
`H51-32869A3A2E96012FCACBF657`	first-look-v5.1.json `/records/44/primary_uses/0`	Historical; current review incomplete
`H51-986E4BC5CB90418F72422BBB`	first-look-v5.1.json `/records/44/primary_uses/1`	Historical; current review incomplete
`H51-2D6C620B3925B91AA29651BE`	first-look-v5.1.json `/records/44/mechanism`	Historical; current review incomplete
`H51-4175907E3A2A548DE4A5EE7E`	first-look-v5.1.json `/records/44/mechanism_level`	Historical; current review incomplete
`H51-0159874E6F00308986C2F40A`	first-look-v5.1.json `/records/44/basic_dosing_orientation`	Historical; current review incomplete
`H51-16C43EB3A32392A3674CF5AE`	first-look-v5.1.json `/records/44/administration_orientation`	Historical; current review incomplete
`H51-90882F0C095F0EE2ECC06D3F`	first-look-v5.1.json `/records/44/renal_and_population_orientation`	Historical; current review incomplete
`H51-FF37A29668AB4476B980B36B`	first-look-v5.1.json `/records/44/key_safety_orientation/0`	Historical; current review incomplete
`H51-7D3C7A877F98F15B783C11FA`	first-look-v5.1.json `/records/44/key_safety_orientation/1`	Historical; current review incomplete
`H51-BD926C7F0FD55029726AE05B`	first-look-v5.1.json `/records/44/key_safety_orientation/2`	Historical; current review incomplete
`H51-5E619D7BB99EFA892D1EE877`	first-look-v5.1.json `/records/44/key_safety_orientation/3`	Historical; current review incomplete
`H51-535EE35E31159206FBF30694`	first-look-v5.1.json `/records/44/coverage_path`	Historical; current review incomplete
`H51-A9887A859536ED51F3C91C02`	first-look-v5.1.json `/records/44/coverage_path_label`	Historical; current review incomplete
`H51-6F2139C3B55DB24D16A0BDF4`	first-look-v5.1.json `/records/44/official_label_url`	Historical; current review incomplete
`H51-8BA564255D580C055D571F8B`	first-look-v5.1.json `/records/44/legacy_title`	Historical; current review incomplete
`H51-88EB2BBBE1C247932B5C720F`	first-look-v5.1.json `/records/44/review_note`	Historical; current review incomplete
`H51-E5D02D3BB5B701DBE44314E4`	first-look-v5.1.json `/records/44/search_text`	Historical; current review incomplete
`H51-7D4D92DC17C96411E4168453`	first-look-v5.1.json `/records/44/official_search_url`	Historical; current review incomplete
`H51-2002F1D0357638931761E999`	first-look-v5.1.json `/records/44/official_access_mode`	Historical; current review incomplete
`H51-920C7FF7BAE76FC69FF1DE98`	first-look-v5.1.json `/records/44/official_access_url`	Historical; current review incomplete
`H51-1D09051B1F9E2C83D00B8A32`	first-look-v5.1.json `/records/44/official_search_query`	Historical; current review incomplete
`H51-30B7113F7EC4FBA8017A0CC0`	first-look-v5.1.json `/records/44/official_access_reason`	Historical; current review incomplete
`H51-EEFB6393B6F063B308597572`	preparation-assessments-v3.8.json `/44/id`	Historical; current review incomplete
`H51-FFCCD6558AF38982DAA76A07`	preparation-assessments-v3.8.json `/44/name`	Historical; current review incomplete
`H51-F413A2D9AC7D4A659D82C09F`	preparation-assessments-v3.8.json `/44/brands`	Historical; current review incomplete
`H51-7B6D3E6AA3F188883FD83DF5`	preparation-assessments-v3.8.json `/44/therapeutic_class`	Historical; current review incomplete
`H51-68147BABFD0B964BE1DB3DE0`	preparation-assessments-v3.8.json `/44/review_version`	Historical; current review incomplete
`H51-84CAB8C693D96AE8C35EE21F`	preparation-assessments-v3.8.json `/44/review_date`	Historical; current review incomplete
`H51-A9EF30C666F38EEF3C5C174F`	preparation-assessments-v3.8.json `/44/release_status`	Historical; current review incomplete
`H51-B5EFED6805C16991002EE6E6`	preparation-assessments-v3.8.json `/44/market_status/status`	Historical; current review incomplete
`H51-C0460F7CA2924A104A0563CC`	preparation-assessments-v3.8.json `/44/market_status/basis`	Historical; current review incomplete
`H51-FC5288D4BA4C9AB79E5F75E8`	preparation-assessments-v3.8.json `/44/ten_point_assessment/exact_formulation`	Historical; current review incomplete
`H51-64478A7DC1C492FE03D0BD9C`	preparation-assessments-v3.8.json `/44/ten_point_assessment/reconstitution_concentration`	Historical; current review incomplete
`H51-A83F9F5D851832D0E0A68A43`	preparation-assessments-v3.8.json `/44/ten_point_assessment/maximum_or_recommended_final_concentration`	Historical; current review incomplete
`H51-D35B6A76D32F2DE2ED6EC042`	preparation-assessments-v3.8.json `/44/ten_point_assessment/appropriate_standardized_containers`	Historical; current review incomplete
`H51-5299D5D3F9E733F9E93C38A1`	preparation-assessments-v3.8.json `/44/ten_point_assessment/adult_dosing_range`	Historical; current review incomplete
`H51-4E192A887A762883D39F603B`	preparation-assessments-v3.8.json `/44/ten_point_assessment/pediatric_dosing_range`	Historical; current review incomplete
`H51-5A4817576C2A0BFF789B25EC`	preparation-assessments-v3.8.json `/44/ten_point_assessment/neonatal_dosing_range`	Historical; current review incomplete
`H51-EB8C4E26BFC1F4A45842791C`	preparation-assessments-v3.8.json `/44/ten_point_assessment/infusion_time`	Historical; current review incomplete
`H51-71D4D064D78D66D382D1B252`	preparation-assessments-v3.8.json `/44/ten_point_assessment/fluid_restriction_alternatives`	Historical; current review incomplete
`H51-F1883F3F47373C00E30A9839`	preparation-assessments-v3.8.json `/44/ten_point_assessment/current_manufacturer_labeling/setid`	Historical; current review incomplete
`H51-5EA1D1D7F2BAF78584D79073`	preparation-assessments-v3.8.json `/44/ten_point_assessment/current_manufacturer_labeling/title`	Historical; current review incomplete
`H51-77C213383D207B41631660D3`	preparation-assessments-v3.8.json `/44/ten_point_assessment/current_manufacturer_labeling/published_date`	Historical; current review incomplete
`H51-799040D93E4462D1A54A3618`	preparation-assessments-v3.8.json `/44/ten_point_assessment/current_manufacturer_labeling/manufacturer`	Historical; current review incomplete
`H51-D6D36E5C3BD5212BFF6A74E7`	preparation-assessments-v3.8.json `/44/ten_point_assessment/current_manufacturer_labeling/match_confidence`	Historical; current review incomplete
`H51-D6674263EE618B7A6A3D7A1E`	preparation-assessments-v3.8.json `/44/ten_point_assessment/current_manufacturer_labeling/url`	Historical; current review incomplete
`H51-899DA0DE1DCE77D47714197D`	preparation-assessments-v3.8.json `/44/field_provenance/exact_formulation/primary`	Historical; current review incomplete
`H51-3E2756E39D1FB83FECC81DF0`	preparation-assessments-v3.8.json `/44/field_provenance/reconstitution_concentration/primary`	Historical; current review incomplete
`H51-EC1E8B31A31079475AD61F7C`	preparation-assessments-v3.8.json `/44/field_provenance/maximum_or_recommended_final_concentration/primary`	Historical; current review incomplete
`H51-A42476AB25AF7C3203FFFEAE`	preparation-assessments-v3.8.json `/44/field_provenance/appropriate_standardized_containers/primary`	Historical; current review incomplete
`H51-351E59FD40B003DDE8AF6AB6`	preparation-assessments-v3.8.json `/44/field_provenance/adult_dosing_range/primary`	Historical; current review incomplete
`H51-27349557128DC0D6425C2A40`	preparation-assessments-v3.8.json `/44/field_provenance/pediatric_dosing_range/primary`	Historical; current review incomplete
`H51-3B64BB3029C22797056B1F5E`	preparation-assessments-v3.8.json `/44/field_provenance/neonatal_dosing_range/primary`	Historical; current review incomplete
`H51-3DFE789C2F23F3130C346B9B`	preparation-assessments-v3.8.json `/44/field_provenance/infusion_time/primary`	Historical; current review incomplete
`H51-7272DB92F1127F8F38A84C19`	preparation-assessments-v3.8.json `/44/field_provenance/fluid_restriction_alternatives/primary`	Historical; current review incomplete
`H51-ACA7A76CDCDC035ADB21A5F2`	preparation-assessments-v3.8.json `/44/field_provenance/current_manufacturer_labeling/primary`	Historical; current review incomplete
`H51-DFF4364C4DAA5C39420CA1BC`	preparation-assessments-v3.8.json `/44/population_applicability/adult/applicability`	Historical; current review incomplete
`H51-2B541ED2B708540FBDD27C62`	preparation-assessments-v3.8.json `/44/population_applicability/adult/guide_generation_allowed`	Historical; current review incomplete
`H51-535376DEF835B48CFEA59C2E`	preparation-assessments-v3.8.json `/44/population_applicability/pediatric/applicability`	Historical; current review incomplete
`H51-5ABC4825F17ADE5B913B3804`	preparation-assessments-v3.8.json `/44/population_applicability/pediatric/guide_generation_allowed`	Historical; current review incomplete
`H51-5EF0CE2C1E12207E29315A97`	preparation-assessments-v3.8.json `/44/population_applicability/neonatal/applicability`	Historical; current review incomplete
`H51-5B816986B3DB0E6513D4C504`	preparation-assessments-v3.8.json `/44/population_applicability/neonatal/guide_generation_allowed`	Historical; current review incomplete
`H51-DFAF4CE8D3BC3B852C4A75E5`	preparation-assessments-v3.8.json `/44/route_presence/structured_dilution`	Historical; current review incomplete
`H51-3226EE5CF4EFE2C51DEA84A8`	preparation-assessments-v3.8.json `/44/route_presence/iv_push`	Historical; current review incomplete
`H51-35842DAA1A21CFB9AACF4401`	preparation-assessments-v3.8.json `/44/route_presence/continuous_infusion`	Historical; current review incomplete
`H51-A6BDE781A7918A46E1B4F8BF`	preparation-assessments-v3.8.json `/44/route_presence/pediatric_source`	Historical; current review incomplete
`H51-E61A086684524653F03DB886`	preparation-assessments-v3.8.json `/44/route_presence/neonatal_source`	Historical; current review incomplete
`H51-96275E048E0E4B458B9D0CE4`	preparation-assessments-v3.8.json `/44/legacy_reference/status`	Historical; current review incomplete
`H51-F2040E832223CFBC6687B07E`	preparation-assessments-v3.8.json `/44/label_resolution/status`	Historical; current review incomplete
`H51-0FA193FE1C0F68FD6FB20602`	preparation-assessments-v3.8.json `/44/concentration_values_detected/0`	Historical; current review incomplete
`H51-668B94AB2A660DA217FFB2EC`	preparation-assessments-v3.8.json `/44/concentration_values_detected/0/low`	Historical; current review incomplete
`H51-A43E381EF5019B1FF1F819D6`	preparation-assessments-v3.8.json `/44/concentration_values_detected/0/high`	Historical; current review incomplete
`H51-EBFB76D5E11232FC17072E13`	preparation-assessments-v3.8.json `/44/concentration_values_detected/0/unit`	Historical; current review incomplete
`H51-AED65E6BD265ACB71DB8F7E9`	preparation-assessments-v3.8.json `/44/concentration_values_detected/0/text`	Historical; current review incomplete
`H51-767FF0E746CAAD9714E9F209`	preparation-assessments-v3.8.json `/44/concentration_values_detected/1`	Historical; current review incomplete
`H51-994B2117492935417DC6416E`	preparation-assessments-v3.8.json `/44/concentration_values_detected/1/low`	Historical; current review incomplete
`H51-5496516B585BC1D16F39BF37`	preparation-assessments-v3.8.json `/44/concentration_values_detected/1/high`	Historical; current review incomplete
`H51-259195B4096C59232D806EAA`	preparation-assessments-v3.8.json `/44/concentration_values_detected/1/unit`	Historical; current review incomplete
`H51-48D677EF1CDFE66FF3674810`	preparation-assessments-v3.8.json `/44/concentration_values_detected/1/text`	Historical; current review incomplete
`H51-1A7FE3A8E1EF6EEB603A493E`	preparation-assessments-v3.8.json `/44/concentration_values_detected/2`	Historical; current review incomplete
`H51-4168FAD26404826B8D3422B4`	preparation-assessments-v3.8.json `/44/concentration_values_detected/2/low`	Historical; current review incomplete
`H51-BF2C331D85FE937A4352743F`	preparation-assessments-v3.8.json `/44/concentration_values_detected/2/high`	Historical; current review incomplete
`H51-9E2471C8324E08408D1454F8`	preparation-assessments-v3.8.json `/44/concentration_values_detected/2/unit`	Historical; current review incomplete
`H51-EE42E54DCF1151941F5B9FC2`	preparation-assessments-v3.8.json `/44/concentration_values_detected/2/text`	Historical; current review incomplete
`H51-66A2BEB83C7CA476E52E7F67`	preparation-assessments-v3.8.json `/44/concentration_values_detected/3`	Historical; current review incomplete
`H51-672FB974B5A2339561E60C93`	preparation-assessments-v3.8.json `/44/concentration_values_detected/3/low`	Historical; current review incomplete
`H51-8E35B8C97A93C2E37EB19219`	preparation-assessments-v3.8.json `/44/concentration_values_detected/3/high`	Historical; current review incomplete
`H51-EF60A5107DFCEF9468A4EF3C`	preparation-assessments-v3.8.json `/44/concentration_values_detected/3/unit`	Historical; current review incomplete
`H51-FD3F89FFC8F6BEAD1A0E4C04`	preparation-assessments-v3.8.json `/44/concentration_values_detected/3/text`	Historical; current review incomplete
`H51-A1C879824298F24A6A5ABE6F`	preparation-assessments-v3.8.json `/44/concentration_values_detected/4`	Historical; current review incomplete
`H51-4F38BD4354207F4B8E5F9443`	preparation-assessments-v3.8.json `/44/concentration_values_detected/4/low`	Historical; current review incomplete
`H51-01E6EF6803321F074B724014`	preparation-assessments-v3.8.json `/44/concentration_values_detected/4/high`	Historical; current review incomplete
`H51-302FB2753E20759B098038F9`	preparation-assessments-v3.8.json `/44/concentration_values_detected/4/unit`	Historical; current review incomplete
`H51-735DE0A7AE75A86991AB7723`	preparation-assessments-v3.8.json `/44/concentration_values_detected/4/text`	Historical; current review incomplete
`H51-7ED657A1EBA5C20C8044BDF0`	preparation-assessments-v3.8.json `/44/source_files/0`	Historical; current review incomplete
`H51-7E0002B607542072F8B10D03`	preparation-assessments-v3.8.json `/44/source_files/1`	Historical; current review incomplete
`H51-B5BAF62D15B1BB492E10C247`	preparation-assessments-v3.8.json `/44/source_files/2`	Historical; current review incomplete
`H51-7C58E7ACC6C1E7D1DDF9D6E3`	preparation-assessments-v3.8.json `/44/source_files/3`	Historical; current review incomplete
`H51-A95AB7946F5C8FE8801CDE6A`	preparation-assessments-v3.8.json `/44/clinical_release_note`	Historical; current review incomplete

All medications Return to medication heading Application top

IV Dilution &Medication Reference

Historical first look: uses, mechanism, dosing context, and administration

Supplemental historical fields

Historical dilution and intermittent infusion preparation

Historical indication and population dosing

Existing dose and route snapshots

Historical renal-function guidance

Historical Common IV uses

Historical Warnings and safeguards

Historical Monitoring

Historical Compatibility

Historical Stability notes

Historical supplemental professional sources

Catalog source fields

Id

Generic name

Brand names

Aliases

Class

Subclass

Summary

Populations

Evidence tier

High alert

Hazardous

Status

Reviewed

Version added

Version updated

Sources

Clinical release verification

Dosing source fields

Id

Generic name

Coverage status

Package insert

Clinical review

Clinical release verification

IV Dilution &
Medication Reference